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ABSTRACT 
 The United States is currently experiencing an epidemic of opioid use, use 
disorder, and overdose-related deaths. While studies have identified several loci 
that are associated with opioid use disorder (OUD) risk, the genetic basis for the 
ability to discontinue opioid use has not been investigated. Furthermore, very few 
studies have investigated the non-genetic factors that are predictive of opioid 
cessation or their predictive ability.  
 In this thesis, I studied a novel phenotype–opioid cessation, defined as 
time since last use of illicit opioids (< 6 months ago as not cease, >1 year ago as 
cease) among persons meeting lifetime DSM-5 criteria for opioid use disorder 
(OUD).  
 In chapter two, I identified novel genetic variants and biological pathways 
that potentially regulate opioid cessation success through a genome wide study, 
as well as genetic overlap between opioid cessation and other substance 
cessation traits. 
 In chapter three, I identified multiple non-genetic risk factors specific to 
	 viii 
each racial group that are predictive of opioid cessation from the same 
individuals analyzed in chapter two by applying several linear and non-linear 
machine learning techniques to a set of more than 3,000 variables assessed by a 
structured psychiatric interview. Factors identified from this atheoretical approach 
can be grouped into opioid use activities, other drug use, health conditions, and 
demographics, while the predictive accuracy as high as nearly 80% was 
achieved. The findings from this research generated more hypotheses for future 
studies to reference. 
 In chapter four, I performed differential gene expression and network 
analysis on mice with different oxycodone (an opioid receptor agonist)-induced 
behaviors, and compared the significantly associated genes and network 
modules with top-ranked genes identified in humans. The pathway cross talks 
and gene homologs identified from both species illuminate potential molecular 
mechanism of opioid behaviors. 
 In summary, this thesis utilized statistical genetics, machine learning, and 
a computational biology framework to address factors that are associative with 
opioid cessation in human, and cross referenced the genetic findings in a mouse 
model. These findings serve as references for future studies and provide a 
framework for personalizing treatment of OUD.  
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CHAPTER ONE: Introduction 
Current epidemic of opioid use disorder (OUD1) 
Socioeconomic impact 	 Medical opioids were prescribed at an increasing rate in the mid to late 
1990s, which was followed by a dramatic rise of potent, synthetic, non-medical 
opioid use2. Opioid overdose is now the leading cause of accidental death in the 
United States (U.S.)3. More than half a million people in the U.S. died from opioid 
overdose from 2000-20153. In addition to the rapid increase of overdose 
mortality, illicit opioid use also resulted in growing rates of emergency room 
visits, babies born with symptoms of drug withdrawal – termed neonatal 
abstinence syndrome (NAS), and Opioid Use Disorder (OUD) treatment 
admissions4. In 2011, the U. S Centers for Disease Control and Prevention 
(CDC) officially declared an opioid epidemic, with the Northeast, Midwest, 
Appalachia, and many southern states being the most severely affected regions 
(Figure 1.1)5. In 2016, more than 90 Americans died from opioid overdoses every 
day, an increase of 21% compared to 20152. From 2010 to 2014, heroin involved 
overdose death has tripled6.  	 The total economic cost of the opioid epidemic is stunning. The Council of 
Economic Advisers (CEA) of the Office of the President of the United States 
published their analysis on the economic burden created by the opioid crisis in 
2015. The total cost of the opioid epidemic was estimated at $504 billion, 
considering both prescription and non-prescription opioid use, which includes 
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$72.3 billion for non-fatal consequences (healthcare cost for OUD therapy, 
criminal-justice cost, reduced productivity) and $431.7 billion in fatality costs7. 
The striking cost estimated for the opioid epidemic highlights for both policy 
makers and researchers the stark need for a better understanding of various 
interventions to mitigate this crisis.  	 Persons with low income, low education, and limited employment 
opportunities are more likely to be the victims of opioid addiction. In 2012, 81% of 
hospital charges for NAS were covered by Medicaid programs, a federal and 
state program that helps with medical cost for people with limited income8. While 
opioid overdose death rates have increased for all education groups, those with 
less than a high school education lost the most years from their estimated life 
expectancy. Persons with lower education might have fewer incentives to quit 
and have more risk factors for engaging in drug use than their more educated 
counterparts9. An association between opioid use and unemployment has also 
been observed, where the opioid crisis was thought to be more severe in areas 
with high rates of unemployment10.  
Opioid classification and mechanisms of action 	 There are several ways to classify opioids. Categorizing by synthetic 
process, there are as naturally occurring compounds (such as morphine and 
codeine), semi-synthetic compounds (such as diamorphine – also known as 
heroin, buprenorphine, and oxycodone), or synthetic compounds (such as 
fentanyl and methadone)11. Opioids can also be classified by their effect on 
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opioid receptors. Opioid agonists (e.g., morphine, diamorphine, codeine, 
fentanyl, methadone, oxycodone) bind tightly to opioid receptors and cause a 
significant conformational change to produces a maximal response, whereas 
partial agonists such as buprenorphine activate opioid receptors to a much 
smaller degree than agonists. Opioids can also be categorized based on the 
types of receptors they bind. All opioid receptors are G-protein coupled receptors 
(GPCR) which include mu, delta and kappa opioid receptors12. Most opioids used 
in clinical practice act mainly through mu opioid receptors, which are responsible 
for generating opioids’ analgesic effects.  	 On the molecular level, opioid receptor activation leads to a series of 
downstream cascades, including inhibition of neurotransmitter release, reduction 
of calcium influx, escalation of potassium efflux, and inhibition of adenylate 
cyclase, an enzyme that breaks down adenosine triphosphate (ATP) to form 
cyclic adenosine monophosphate (cAMP)13. When an opioid binds to its GPCR, 
the alpha subunit of GPCR disassociates from the beta and gamma G-protein 
complex. The disassociated alpha subunit interacts with the G-protein gated 
potassium channels and leads to increased potassium efflux, while the beta and 
gamma G-protein complex inhibits calcium conductance by directly binding to the 
channel, causing cellular hyperpolarization resulting in neural activity inhibition. 
The C-terminal domain of the GPCR is further phosphorylated upon opioid 
binding, which recruits and binds to the adapter protein beta-arrestin14. The 
phosphorylated arrestin-bound GPCR activates MAPK pathways, which 
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participate in multiple cellular processes, including cell proliferation, 
differentiation, apoptosis, transcription factor regulation, and protein scaffolding15.  	 The positive reinforcement (reward) of opioid results primarily through the 
dopamine system.	At the physiological level, dopaminergic neurons are located 
mainly in the mid brain ventral tegmental area. Their axons project to the striatum 
(including nucleus accumbens and putamen), amygdala, and prefrontal cortex15. 
The ventral tegmental area and nucleus accumbens represent the mesolimbic 
dopaminergic reward system, which mediates opiate reinforcement16. Opioids 
when bound to mu receptor, it causes a disturbance of potassium channel 
activity and results in a reduction of excitatory neurotransmitters such as 
substance P and glutamate release in and from the prefrontal cortex15,17. The 
neuron hyperpolarization and reduced release of the inhibitory neurotransmitters 
contribute to opioid’s analgesic effect and addictive properties.  	 Pharmacological actions of opioid agonists have been well studied. 
Opioids have a strong effect on the central nervous system and result in 
analgesia, sedation, euphoria, dysphoria, tolerance and dependence, and also 
impact the cardiovascular system leading to mild bradycardia and peripheral 
vasodilatation. They also affect the respiratory system, leading to respiratory 
depression, cough suppression; the gastrointestinal system, leading to nausea 
and vomiting; the muscular system, leading to muscle rigidity and pupil 
constriction; and the immune system, leading to immune depression18.  
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Clinical criteria for OUD and current treatment  	 The 2018 International Classification of Diseases, 10th Revision, Clinical 
Modification (ICD-10-CM)19 and American Psychiatric Association's Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) both have a set 
of complex criteria to quantify opioid use and its related conditions. DSM-5 
considers 11 OUD symptom criteria that account for loss of control, social 
problems, risky use, and pharmacological problems. An OUD diagnosis requires 
that a person meet at least two criteria within a 12-month period. Severity of OUD 
is defined by the number of symptoms as follows: mild (2-3 symptoms), moderate 
(4-5 symptoms), or severe (>6 symptoms) (Table 1.1)20.  According to DSM-5, 
early opioid remission lasts 3-12 months and sustained remission requires a 
period of at least 12 months without any OUD diagnostic criteria (except for 
craving)21. ICD-10-CM opioid related disorder criteria (Table 1.2)22 are generally 
similar to DSM-5, for example, there are two remission codes corresponding to 
opioid use severity. However, ICD-10-CM does not define withdrawal for opioid 
abuse23.  	 There are various behavioral and pharmacological interventions to treat 
OUD. Behavioral interventions include help by well-trained counselors to identify 
risk behaviors24 and by patient advocates, and self-help25. Pharmacological 
interventions mostly target mu opioid receptors. Methadone, for example, is a 
long-acting opioid agonist that has been shown to reduce relapse rate, facilitate 
behavioral therapy, and enable OUD sufferers to live a normal life26. Medical use 
 	
6 
of methadone produces minimal tolerance, reduces craving, and has been 
associated with positive long term outcomes27,28. Naltrexone is a mu receptor 
antagonist; it lessens the potential for relapse by tightly binding to the mu opioid 
receptor without producing pleasure. Naltrexone has lower compliance than 
methadone because one must be fully withdrawn from all opioids agonists to 
avoid withdrawal29. Buprenorphine is a mu receptor partial agonist; patients with 
opioid physical dependence (display symptoms such as gastrointestinal upset or 
gooseflesh skin) are likely to withdrawal. 
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Figure 1.1 Drug overdose death rate by state5.  
Northeast, Midwest, Appalachia, and several southern states are the most 
severe regions.	
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Table 1.1 DSM-5 OUD criteria20.  
OUD is defined as a problematic pattern of opioid use that leads to serious 
impairment or distress. OUD patients must meet at least two of the following 
symptoms within a 12-month period. Mild OUD: 2-3 symptoms, moderate OUD: 
4-5 symptoms, severe OUD: more than 6 symptoms.  
 
Loss of Control 
1 Substance taken in larger amounts or for a longer time than intended 
2 Persistent desire or unsuccessful effort to cut down or control use of a substance 
3 Great deal of time spent obtaining, using, or recovering from substance use 
4 Craving (a strong desire or urge) to use opioids 
Social Problems 
5 Continued opioid use that causes failures to fulfill major obligations at work, school, or home 
6 Continued opioid use despite causing recurrent social or personal problems 
7 Important social, occupational, or recreational activities are reduced because of opioid use 
Risky Use 
8 Recurrent opioid use in dangerous situations 
9 Continued opioid use despite related physical or psychological problems 
Pharmacological Problems 
10 Tolerance (the need to take higher doses of a drug to feel the same effects, or a reduced effect from the same amount) 
11 Withdrawal (the experience of pain or other uncomfortable symptoms in the absence of a drug) 	
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Table 1.2 ICD10 opioid dependence criteria22. 	
1 a strong desire or sense of compulsion to take opioids 
2 difficulties in controlling opioid-use behaviors in terms of the onset, 
termination or levels of use 
3 a physiological withdrawal state when opioid use has ceased or been 
reduced, as evidenced by one of the following 
 a. the characteristic withdrawal syndrome 
 b. use of opioids (or closely related substances) with the intention of relieving 
or avoiding withdrawal symptoms 
4 evidence of tolerance, such that increased doses of opioids are required to 
achieve effects originally produced by lower dose 
5 progressive neglect of alternative pleasures or interests because of opioid 
use; increased amounts of time spent to obtain opioids or to recover from 
their effects 
6 persisting with opioid use despite clear evidence of overtly harmful 
consequences, such as depressive mood states consequent to periods of 
heavy substance use, or drug-related impairment of cognitive functioning 
(efforts should be made to determine that the user was actually, or could 
be expected to be, aware of the nature and extent of the harm) 	 	
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Studies of genetic and phenotypic factors relating to OUD in human  
Studies of human genetics overview 
Linkage and candidate gene studies  	 To identify genes that are associated with addictive traits, a good first step 
is to evaluate evidence of heritability of such traits. More than two decades ago, 
genetic linkage analysis and candidate gene studies were popular tools used to 
identify chromosome regions that are associated with a trait. Linkage studies 
make it possible to identify chromosomal locations of the disease-associated 
genes based on the fact that the shorter the physical distance between two 
genes on a chromosome, the less likely recombination will occur between them 
during meiosis. Linkage studies are particularly useful in diseases that are 
inherited in a Mendelian fashion, but such studies require data from multiple 
family members including at least two affected persons and, thus, are often 
limited by sample size30. Regions on chromosome 17 in African Americans 
(AAs), European Americans (EAs), and Han Chinese have been linked to opioid 
dependence31,32. 	 Linkage studies can establish the genetic basis of a trait, but often lack the 
resolution necessary to point to specific genes involved in a trait. In contrast, 
hypothesis-based candidate gene studies focus on genes that have been 
previously related to the disease experimentally. By comparing the frequency of 
single nucleotide polymorphisms (SNPs) in persons with disease and controls, 
one can evaluate whether a gene is associated with the disease33. However, 
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several limitations should be noted such as the possibility of false positive 
associations due to population admixture, multiple testing correction issues due 
to testing the same SNP in different traits or multiple SNPs for the same trait, and 
selection bias due to limited and sometimes incorrect knowledge about 
physiology30. The mu-opioid receptor (OPRM1), the delta-opioid receptor 
(OPRD1), the dopamine D2 receptor (DRD2), and brain-derived neurotrophic 
factor (BDNF) have been extensively studied as candidate genes for opioid 
dependence in several populations34-36, the polymorphism of these genes have 
shown to be affecting the traits.  
Genome-wide association studies (GWAS) 	 With the development of microarray chip technology, an extremely large 
number of markers can be assessed for association with disease in a single 
experiment. GWAS use hypothesis-free methods for identifying associations 
between genetic loci and traits. GWAS usually evaluate association of disease 
status with common SNPs and rely on linkage disequilibrium (LD), population 
level links between the SNPs and the causal markers, which may or may not be 
tested directly37. Given the millions of markers tested directly or imputed using 
LD information from population reference panels, an alpha level of 5×10-8 is 
generally used as a significance threshold to correct for the large number of 
tests. GWAS require thousands or tens of thousands of samples to achieve 
adequate power to identify SNPs with a small effect on disease risk, and the true 
causal variants related to the association signal might not be located in the genes 
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containing the top-ranked variants. The number of signals identified by GWAS for 
a specific trait depends on the number of loci affecting the trait, the allele 
frequencies and effect sizes of the loci, sample size, and trait heterogeneity38. 
Potassium voltage-gated channel subfamily G member 1 (KCNG2) was the first 
gene identified from GWAS for opioid dependence in both AAs and EAs39. 
Subsequently, a SNP near repulsive guidance molecule BMP co-receptor A 
(RGMA) was associated with opioid dependence in an EA sample40. 
Rare variant studies 	 Although numerous discoveries have been made identifying common 
variants of OUD through GWAS, much of the heritability remains unexplained. 
Many Mendelian disorders and rare diseases are caused by highly penetrant rare 
variants41. Natural selection tends to eliminate deleterious alleles, and loss of 
function variants are especially rare42. Next generation sequencing and high 
confidence genotype imputation have made it possible to analyze infrequent 
variants. Given the limited statistical power of a single variant analysis approach 
using GWAS, several statistical methods were developed for rare variant 
analysis. These methods include (1) the burden test, which aggregates rare 
variants into gene- or region-based scores that are used for an association test; 
(2) the adaptive burden test, which adds adaptive weights on top of the burden 
test to magnify the effect of deleterious variants; (3) variance-component test, 
which tests the variance of genetic effects; and (4) the combined test, which 
combines the benefit of both burden and variance-component tests43. However, 
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to date there are not any publications studying rare variants in opioid related 
traits. 
Enriched pathways analysis 	 Associations with variants and genes obtained from GWAS usually do not 
provide a sufficient explanation of disease mechanisms when considering genes 
individually. Other methods can translate these findings into a more biologically 
coherent understanding of the underlying disease processes. Enriched pathway 
analyses, including gene over-representation and aggregate gene scores, can 
help with this. Both analyses form gene sets based on a biological process or 
certain molecular functions derived from information in existing databases such 
as Gene Ontology44. Steps to carry out the over-representation analysis include 
forming a list of top genes from GWAS, comparing the number of GWAS genes 
that are members of each gene set to those who are not members using 
hypergeometric distribution or binomial approximation to infer statistical 
significance45. Many of these methods have been implemented as web-based 
tools, such as Enrichr46. As a limitation, the over-representation method ignores 
genes that are not in the GWAS selected gene list and the result depends on the 
cutoff for the gene selection. The aggregate score approach overcomes this 
limitation by including all the genes from GWAS in the analysis. One of the most 
representative methods is gene set enrichment analysis (GSEA), which aims to 
calculate if gene scores in gene set !	are different from gene scores in genes 
outside of !. For GSEA, each SNP is assigned to a gene followed by 
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computation of SNP-based gene scores, then it compares the rank of the genes 
included in a pre-specified gene set to the rank not included in the gene set, 
based on the Kolmogorov Smirnov test45.  There are several limitations of the 
enriched pathway analysis approach. For example, the use of a gene set might 
be limited by current biological knowledge; furthermore, many GWAS SNPs may 
not be located in genes or may overlap several genes. Using enriched pathway 
analysis, genes identified through opioid dependence case control studies are 
overrepresented in calcium and potassium pathways 39. 
 
Human SUDs behavioral research through large epidemiology studies  	 Various epidemiology studies use survey data to derive DSM-5 criteria to 
classify types of SUDs in susceptible groups, such as adults47,48,people with 
comorbid psychiatric diseases49, people from different geographical regions50, 
and unique social groups51,52. Although the goals of these large epidemiological 
studies are to identify factors that influence the distribution and etiology of SUDs 
for prevention or intervention efforts, a limited amount of factors (e.g. 
sociodemographic characteristics, comorbidity, disability, and treatments) were 
previously analyzed48. Moreover, many of these studies use simple statistical 
methods such as regression or correlation to determine the influence of a specific 
factors 48,52. With the increasing availability of electronic health records (EHRs) 
for epidemiologic research, more opportunities are available for researchers to 
access high dimensional data and identify additional factors associated with 
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SUDs. Such datasets with thousands of variables might not be efficiently 
analyzed with simple regressions and would suffer from overfitting and 
insufficient power issues due to the increasing number of covariates53. 
 
Deriving patterns from the high dimensional datasets using machine 
learning 	 Data mining using machine learning is increasingly used to identify 
abnormalities, classify patients, facilitate diagnoses, and evaluate prognoses. 
Feature selection as a data mining method can be effectively used to remove 
irrelevant data, increase learning accuracy, and improve comprehensibility. 	 Since an exhaustive search for optimal feature subsets is not feasible in 
most cases, alternative strategies have been proposed in three main categories: 
filter, wrapper, and embedded methods54. The filter methods select features 
based on a performance measure independent of the prediction/classification 
method used in the later stage. Information gain, Euclidean distance, and p 
values from the univariate tests are examples of such performance measures. 
Wrapper methods consider feature subsets by the quality of performance on a 
modeling algorithm. The evaluation is performed on each subset using the same 
search rule, such as recursive feature elimination (RFE) 55. Wrapper methods 
have been proven to perform better than filter methods while taking longer time 
to execute. Embedded methods are greedy search based algorithms that 
perform intrinsic feature selection. One of the popular techniques in embedded 
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methods is stepwise regression. Depending on the model, one might start with 
an empty list and recursively add variables one by one or start with a full list of 
variables and recursively remove variables one by one until the variable set 
collectively achieves the best fit56. Limitations of using stepwise regression 
include its limited ability to find the global optimization, method instability with 
different models, and the maximum number of variables that can be considered 
56,57. 	 Regression based models have been used for estimating the relationship 
between a single dependent variable with one or more independent variables. 
However, there are limitations to regression based methods such as the 
assumption of linearity between the independent and dependent variables, the 
assumption of little or no multicollinearity between dependent variables, and 
normally distributed residuals. With the emergence of other machine learning 
algorithms such as neural networks, support vector machines, and random 
forests, several of these limitations have been addressed. The logic behind some 
of the popular feature selection methods employed in Chapter three are 
described in Table 1.2. 
Logistic Least absolute shrinkage and selection operator (LASSO) 	 LASSO is a regression based model that uses L1-norm (absolute value) 
regularization to shrink the effect estimate of irrelevant variables to zero and it 
has been popularly used in biological studies 58. LASSO minimizes the residual 
sum of squares subject to the sum of the absolute value of the coefficient being 
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less than a constant59. LASSO is widely used especially for problems where the 
number of variables p exceeds the number of observations $. However, when p > 	$, the LASSO criteria is not strictly convex and thus might yield an unstable 
solution60. During feature selection, LASSO randomly picks one variable from a 
group of correlated variables. 
Linear–Support vector machine (linear-SVM) 	 SVM is a discriminative classifier best known for the ‘kernel trick’ – the 
ability to transform the value of each feature into a different dimension via a 
kernel function -- and is widely used in high dimensional genomic data61,62. SVM 
finds the best linear separating hyperplane with the maximal margin between two 
classes of data. RFE has proven to yield better classification performance using 
SVM 63. To avoid overfitting, a regularization parameter term is added to allow for 
a certain degree of misclassification.  
Random forest (RF) 	 RF is an ensemble classification and regression method that yields high 
classification accuracy. RF is able to achieve both low bias and low variance by 
averaging across multiple low bias, high variance decision trees. Each decision 
tree is constructed by sampling with replacement from the available training data 
pool. Gini impurity, a measurement based on information criteria, is used to 
indicate the feature importance64. Variables that lead to higher reduction in Gini 
impurity are ranked higher than those who don’t. Similar to linear-SVM, RFE is 
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used to select features based on the Gini importance of the variables. 
Deep Neural Network (DNN) 	 DNN uses multilayer perceptron to process knowledge and make 
predictions. The structure and function of DNN are based on our understanding 
of the nervous system, where neurons are interconnected in such a way that they 
can store information and determine if a signal is strong enough to be passed on. 
A standard DNN contains an input layer, where each node takes in a set of 
information from the input; one or several user-defined hidden layers, where 
every node from each layer is fully connected to all the nodes from the previous 
layer, as well as to all the nodes from the next layer; and an output layer that 
yields the prediction result. As the building block of DNN, each node performs the 
sum of a linear combination from the inputs of the previous layer with certain 
weights and biases. After summation, information is subject to a linear or non-
linear transformation by an activation function. This step allows DNN to model 
any linear or non-linear relationships between the inputs and outcome. Feature 
selection in DNN has been studied by several groups, and more details will be 
described in chapter three.  
Other methods 	 Other feature selection methods using machine learning, such as genetic 
algorithms (GAs) and hybrid methods, should also be noted. GA is a stochastic 
method for finding optimization using the theory of natural evolution and is best 
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known for its ability to efficiently search large spaces with little known a priori65. A 
user-defined classifier (DNN, SVM, etc.66) can be used for GA. An initial set of 
variables are randomly picked by each classifier and trained on a training set. 
The performance (fitness) of each classifier is then evaluated using an 
independent dataset. Based on the fitness of each classifier, top classifier-
associated features are picked for the next round of evaluation while new sets of 
features are created by “crossing over” or “mutating” features from these 
classifiers. “Crossover” and “mutation” are special strategies used by GA in order 
to find the optimized feature space; both strategies adopt partial inputs from the 
high-performing classifiers and generate more feature combinations for further 
testing. The fitness evaluation, selection, crossover, and mutation steps are 
repeated until a stopping criterion is met, where the inputs from the most fitted 
classifier would contain the most relevant features. GA does not require any a 
priori knowledge of the problem under investigation, but is very computationally 
expensive. We did not pursue this method given that GA iteratively builds many 
predictive models and can take a long time to converge. The hybrid method is an 
application of a combination of several machine learning methods, such as 
linear-SVM coupled with LASSO, DNN coupled with linear-SVM, etc. The hybrid 
method application is left as a future direction to explore possible improvements 
based on what was observed using the primary methods. 	 	
 	
20 
Table 1.3 Characteristics of the selected machine learning methods.  
Pros and cons of LASSO, linear-SVM, RF and DNN as feature selection 
methods. LASSO is an embedded method that performs feature selection and 
outcome prediction simultaneously. Both linear-SVM and RF uses a wrapper 
method – recursive feature elimination to select important variables. For DNN, 
we used a filter based method, which picks the inputs based on their net 
contributions to the next node (see Chapter three). LASSO: Logistic Least 
absolute shrinkage and selection operator, linear-SVM: linear support vector 
machine, RF: random forest, DNN: deep neural network.   
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 Pros Cons note 
LASSO sparsity, leaves few 
correlated variables, 
parametric, model inter-
variable relationships, 
simpler parameter 
tuning, provides 
directionality between 
the predictors and the 
outcome  
unstable, more biased 
than OLS 
linear 
Linear-
SVM 
uses "support vectors" to 
make decision, has 
guaranteed optimality, 
provides directionality 
between the predictors 
and the outcome  
Nonparametric, picks 
correlated variables, non-
parametric, less effective 
in noisy data 
linear 
RF  An ensemble method, 
uses how often a feature 
is selected for splitting 2 
classes as a criteria for 
feature importance 
Nonparametric, picks 
correlated variables, no 
directionality between the 
predictors and the 
outcome 
non-linear 
DNN models intricate inter-
variable relationship (e.g 
interactions), powerful in 
detecting complex 
patterns, framework 
allows flexible sub 
method selection 
Nonparametric, picks 
correlated variables, low 
interpretability, trial and 
error-based, more 
hyperparameters to tune, 
not easy to find the global 
minimum, requires a 
higher volume of data, no 
directionality between the 
predictors and the 
outcome 
non-linear 
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Studies of genetic and phenotypic factors relating to OUD in non-human 
model organisms 
Overview of non-human model organism studies 
Animal model organisms for addiction studies 	 Experimenters are able to use animals to model distinct components of 
the addiction process, and evaluate a range of behaviors from simple (e.g. acute 
drug responses) to more complex behaviors (e.g. drug seeking, self-
administration, and relapse). Genetic studies in model organisms (such as C. 
elegans, Drosophila, zebrafish, and mouse) have led to the identification of novel 
and previously unsuspected genes affecting addictive processes. C. elegans has 
many attributes that make it a useful model for studying neurobiological aspects 
of addiction, for instance it has a remarkably small and well-characterized 
nervous system, fully sequenced genes, short reproduction cycle (3 days), and 
the ability to self-fertilize67. Similar to C. elegans, Drosophila models are low cost 
and size, and relatively easy to handle68. Around 75% of human disease genes 
have homologs in Drosophila68. Behavioral assays in zebrafish allow exploration 
of acute drug response and drug associated reinforcements, such as drug-
induced locomotor activity and withdrawal behaviors69.  
Mice as a commonly used model organism for addiction 
 Mammalian model organisms offer the most comprehensive set of 
genomic and molecular tools for identifying addiction related traits 70,71. 99% of 
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mouse genes have human homologues while 95% of mice variants have human 
counterparts72, which allows for translation of gene function to humans73. Mice 
are relatively easy to breed and require a limited amount of space to house73,74. 
Importantly, environmental factors and drug administration can be precisely 
controlled, allowing more accurate research on certain relevant genetic factors. 
Mice behavioral paradigms are well-developed, some of which permit rapid 
collection of phenotypes on a relatively large scale. Mice and humans show a 
considerable amount of overlap in neural pathways associated with addictive 
drugs75,76. Gene editing tools such as CRISPR allow one to rapidly develop 
models with a desired genotype for demonstrating genetic causality77,78. 
 However, it is still challenging to model the complexity of addiction in 
humans using mouse models. While we can model aspects of the human 
condition of drug seeking and taking, for example, by manipulating economic 
cost (e.g. demand curve analysis) or drug availability (schedules of access), 
these do not perfectly mimic many factors of addiction that are unique to human 
society (e.g. continued use despite social, legal, or financial consequences).  	 There is a large amount of methodological overlap between mice and 
humans when it comes to studying the genetic underpinning of addiction traits. 
On top of the genetic approaches listed above, described below are additional 
genetic methods that are commonly used in mice to study addiction traits. 
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Quantitative trait locus (QTL) 	 QTL mapping locates genetic loci and estimates their effect in regulating 
quantitative traits. The idea of QTL mapping is similar to linkage studies in 
humans, where the genetic variants responsible for addiction are detected by the 
statistical association between the variations and genetic markers in backcrossed 
or intercrossed progeny derived from crossing two inbred strains79. The discovery 
potential of QTL mapping is limited to the polymorphism sites between the inbred 
parental strains, and as a result, the QTL intervals are often too large to identify 
causal variants for a lower generation of mouse strains (such as F2 cross) 
because the strains have only experienced a limited amount of recombination 
events. Several QTL studies have studied loci associated to opioid phenotypes 
using inbred mouse strains80,81, specifically, one study has revealed an interval 
on chromosome 11 associated with opioid sensitivity82, and several candidate 
genes on chromosome 7 relating to opioid response83. 
Transcriptomic and gene network analysis 	 Using animal models allows use of RNA-sequencing techniques to 
investigate gene expression profiles in multiple tissue types at multiple time 
points in response to drug treatment or in subjects with different genetic 
backgrounds84. The recent development of single-cell RNA-sequencing allows for 
the profiling of gene expression patterns in individuals cells and the classification 
of different neural cell types85. Transcriptomic analysis also includes the study of 
alternative splicing, where the different genotypes of interest or the drug 
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treatment could lead to increased proteome diversity and regulate protein 
function86. Opioid dependent transcriptional response has been widely studied in 
several neural cell types in mice87,88. 	 Gene network analysis is an additional way to yield biological insight from 
a list of pre-selected genes. Constructing networks from co-expressed genes can 
lead to new discoveries in gene functions, gene-gene interactions, and potential 
biological mechanisms89. For example, immune-signaling and ERK1/2 were 
found as novel genetic markers for multiple addiction phenotypes through gene 
network analysis using genes previously identified90. 
 
Mice behavioral studies  	 There are many methods available for studying the incentive, learning, 
and drug reward behaviors in rodent models, which can further our 
understanding of the neural basis of addiction. Below are a subset of behavioral 
assays in mouse models that can be used to investigate drug sensation, 
rewarding effect, and withdrawal behaviors that may translate to humans.   
Rewarding and aversive effects of drugs 	 Conditioned placed preference (CPP) is a preclinical behavioral test to 
study drug reward and aversion. Animals are trained to associate distinct 
environments with drug/non-drug treatment. On the test day, under drug-free 
conditions, animals are given the opportunity to choose which environment they 
prefer to spend the most time, adjusting for the baseline preference. The CPP 
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paradigm requires little training when compared to self-administration procedures 
and can be combined with other techniques to elucidate the subjective effects of 
drugs53. 
Drug induced locomotor activity  	 Locomotor activity is used to assess whether a drug possesses 
psychostimulant or sedative effects by measuring the distance the experimental 
animal traveled in the open field after administration of the drug. However, while 
opioids induce sedation in humans91,  they can have either sedative or stimulant 
effects in mice or rats based on dosage92,93. Although drug induced locomotor 
activity is sometimes used as a proxy to evaluate the drug’s rewarding effect, 
locomotor activity and rewarding effects of drugs are regulated by different 
circuitries in mice94.	
Drug withdrawal behaviors 	 Opioid withdrawal is known to induce anxiety in humans. Elevated plus 
maze (EPM) is a test used to evaluate anxiety-like behavior induced by drug 
withdrawal. EPM consists of two open arms and two closed arms of equal length 
that are oriented along a single plane and elevated a certain distance above the 
floor95. Previous research has suggested that both spontaneous and naloxone-
precipitated withdrawal from opioids in rats causes anxiogenic-like effects 
(reduction time spent in the open arms) in the EPM96. Mice drug withdrawal 
induced anxiety-like behaviors are displayed differently, where they tend to 
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spend longer time in the open arms during both spontaneous and naloxone-
precipitated opioid withdrawal97,98.	
Specific aims 	 The primary goal of this thesis project is to identify genetic and phenotypic 
factors underlying opioid cessation, specifically the ability of people who meet 
DSM-5 OUD criteria to quit opioid use for at least one year. The three aims of 
this project (listed below) combine the use of GWAS, machine learning methods, 
and a mouse model with chronic opioid treatment as research tools to find 
potential variants, genes, pathways, networks, and behavioral variation that 
provide insights into understanding opioid cessation.  	 Aim 1: Identify common variants associated with opioid cessation through 
GWAS performed using multi-ethnic (AAs and EAs) samples, and strengthen the 
most promising findings in an independent EA sample. Potential biological 
pathways influencing opioid cessation will be evaluated using enriched pathway 
analysis that incorporates the GWAS summary information. In addition, the 
genetic overlap between opioid cessation and other SUD traits using GWAS 
results obtained from a large population-based sample deposited in the UK 
Biobank.  	 Aim 2: Identify phenotypic factors that are predictive of opioid cessation 
by applying several machine learning methods to analyze several thousand of 
variables related to drug use, mental and other medical conditions, and 
demographic and lifestyle factors obtained from 2557 EA and 1192 AA 
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individuals meeting DSM-5 criteria for OUD.  	 Aim 3: We used a mouse model to investigate possible opioid cessation 
genes; particularly, we employed a reduced genetic complexity cross between 
mouse substrains that display differential opioid sensitivity and withdrawal 
behaviors. Given the limitations in modeling human opioid cessation using mice, 
we aimed to cross- referenced trans-regulated genes and networks associated 
with a QTL regulating opioid sensitivity to human opioid cessation genes that 
were identified from GWAS. This framework provides an indirect way to 
potentially validate genes identified from association studies in humans by 
generating hypotheses regarding common biological pathways and can be tested 
in vivo. 	
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CHAPTER TWO: GWAS of Opioid Cessation 
Abstract 	 The United States is currently experiencing an epidemic of opioid use, use 
disorder, and overdose-related deaths. While studies have identified several loci 
that are associated with OUD risk, the genetic basis for the ability to discontinue 
opioid use has not been investigated. We performed a genome-wide association 
study (GWAS) of opioid cessation in 1,130 African Americans (AAs) and 2,919 
European ancestry (EAs) participants recruited for genetic studies of opioid, 
cocaine, or alcohol use disorders and who met DSM-5 criteria for OUD. Opioid 
cessation was defined as abstinence from opioids for at least one year before the 
interview date. We examined the association of opioid cessation status genome-
wide using generalized estimating equations to account for correlations among 
related individuals and a model that included terms for imputed single nucleotide 
polymorphism (SNP) dosage, sex, age and the first five principal components of 
ancestry. Association tests performed separately within each ethnic group were 
combined by meta-analysis with summarized results obtained from the 
Comorbidity and Trauma Study. Although there were no genome-wide significant 
associations, we found suggestive associations with nine independent loci, three 
of which were of biological relevance: rs4740988 in PTPRD (p=2.24×10-6 in AAs 
and EAs combined), rs36098404 located in the intron of MYOM2 (p=2.24×10-6 in 
EAs), and an intron variant rs592026 of SNAP25-AS1 (p=6.53×10-6 in EAs). 
Pathway analysis identified significant pathways in EAs that are related to vitamin 
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D metabolism (p = 3.79×10-2) and FGF signaling (p = 2.39×10-2). We also found 
evidence of shared genetic underpinnings between opioid cessation and risk of 
other substance use disorders, cessation of smoking and drinking, and chronic 
back pain in the UK Biobank by evaluating the association of polygenic risk 
scores constructed from summary statistics of these phenotypes with opioid 
cessation. These results provide evidence for genetic influences on opioid 
cessation, suggest genetic overlap with other relevant traits, and may indicate 
potential novel therapeutic targets for OUD.  
Introduction 
	 Non-prescribed use of opioid analgesics has become a significant global 
problem that affects the health and economic welfare of society99. In 2017, more 
than 47,000 Americans died of an opioid overdose, and about 40% of these 
deaths involved prescription opioids100. The U.S Department of Health and 
Human Services declared a public health emergency in 2017 to address the 
national opioid crisis101. Opioid maintenance and cognitive behavioral 
approaches are effective102,103, but they have limited long-term value reflected by 
high dropout and relapse rates104. The nearly 80% of Americans with opioid use 
disorder (OUD) who do not seek treatment6 adds to the burden of this 
devastating public health problem. Several studies have identified genetic 
variants related to OUD39,105, which is highly heritable (h2 = 0.43,0.50)106. The 
lack of published reports about genetic factors that influence successful 
cessation of illicit opioids and prescription opioid misuse may be due to the 
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challenge of assembling sufficiently large cohorts with the requisite information 
about opioid use and cessation, high relapse rate, and non-standard definitions 
of cessation107,108. 
	 Here, we present results from the first genome-wide association study 
(GWAS) for opioid cessation among persons meeting DSM-5 criteria for OUD21 
in a sample of African Americans (AAs) and European Americans (EAs) recruited 
for genetic studies of substance use disorders (SUDs)109,110. We also identified 
genetic overlap between opioid cessation and other SUDs-related traits in the UK 
Biobank (UKBB)111. 
Material and Methods 
Participants and Diagnostic Procedures 	 Participants for this study were ascertained from two sources. The Yale-
Penn sample includes 6,188 African American (AA) and 6,835 European 
ancestry (EA) participants who were enrolled in genetic studies of dependence 
on opioids, cocaine or alcohol between 2000 and 2017 through treatment clinics 
at the University of Connecticut Health Center, Yale University School of 
Medicine, the Medical University of South Carolina, University of Pennsylvania, 
and McLean Hospital in Belmont, Massachusetts112,113. This cohort included 
affected sibling pairs and additional family members, as well as unrelated cases 
and controls. Probands with a schizophrenia or schizoaffective disorder were 
excluded112,113. Psychiatric interviews using a computerized version of the Semi-
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Structured Assessment for Drug Dependence and Alcoholism (SSADDA)114,115 
were administered to all participants and diagnoses of dependence on various 
substances and other psychiatric disorders were derived according to DSM 
criteria. A second sample of EAs was derived from the Comorbidity and Trauma 
Study (CATS) which has been described previously. 116 In brief, opioid 
dependent (OD) cases ages 18 or older were recruited from opioid substitution 
therapy (OST) clinics in metropolitan Sydney, Australia. Persons who had recent 
suicidal intent or psychosis were excluded. Controls were recruited from 
neighborhoods geographically proximal to the OSTs and excluded persons who 
used opioids recreationally more than five times (i.e., only OD cases were 
included in this analysis). Participants were interviewed using the SSADDA – 
Australia (SSADDA-OZ)117 which was used to derive DSM-IV SUD diagnoses. 
Institutional review board approval for this study was obtained at all participating 
institutions, and written informed consent was obtained from all study 
participants. 
Cessation Phenotype Definition 	 Participants who were eligible for this analysis met at least two DSM-5 
OUD criteria, corresponding to a lifetime diagnosis of OUD. Current opioid 
cessation status was determined based on the response to the SSADDA 
question, “When was the last time you used an opioid drug (including illicit 
methadone)”. We classified individuals who last used an opioid >1 year before 
the date of interview as having successfully ceased opioid use and those whose 
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last use of an opioid was <6 months before the interview date as not ceased 
opioid use. Other opioid users whose self-reported last use was between 6 
month and a year ago were excluded from the analysis. The ascertainment 
scheme and filtering steps to arrive at the sample of 1,130 AAs and 1,859 EAs 
informative for the opioid cessation study are shown in Figure 2.1. Persons in the 
CATS dataset with a lifetime diagnosis of OD were classified as ceased if the last 
use of an opioid was at least one year before the age at the last interview 
(n=337) or non-ceased if the age of last use of an opioid was the same as the 
age at the last interview (n=723). OD cases in the CATS sample who last used 
an opioid exactly one before the last interview were excluded. Characteristics of 
all individuals included in the GWAS are shown in Table 2.1.  	  
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Figure 2.1. Derivation of opioid cessation study samples from the Yale-
Penn dataset.  
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Table 2.1.  Characteristics of the participants for the opioid cessation 
GWAS 
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Genotyping, Imputation and Quality Control 	 DNA specimens in the Yale-Penn sample were genotyped using the 
Illumina HumanOmni1-Quad v1.0 microarray (OMNI) which contains 988,306 
autosomal SNPs, the Illumina Infinium Human Core Exome microarray (HCE) 
which contains 265,919 exome-focused SNPs and approximately 240,000 
tagging SNPs to allow genome-wide imputation, or the Illumina Multi-ethnic 
Global Array (MEGA) which contains 1,779,819 markers that have appreciable 
frequency in at least one of five major populations in order to maximize genome-
wide imputation accuracy. Genotyping was performed at the Yale Center for 
Genome analysis except for a group of participants (822 AAs and 955 EAs) who 
were genotyped using the OMNI1 array at the Center for Inherited Disease 
Research (CIDR). DNA specimens from the CATS sample were genotyped at 
CIDR using the Illumina Human660W-Quad BeadChip. Quality control of 
genotype data was performed as previously described39. Briefly, individuals with 
a call rate <98% and variants with minor allele frequency (MAF) <1% were 
excluded. Pairwise identity-by-decent (IBD) was calculated with PLINK118 to 
determine genetic relatedness among individuals in the sample. Individuals with 
a pairwise IBD estimate > 25% were assigned to the same family. Self-reported 
males with X chromosome heterozygosity >20% and self-reported females with X 
chromosome heterozygosity < 20% were excluded. Population substructure in 
the entire sample was evaluated by analysis of principle components (PC) of 
ancestry using Eigensoft119 and the multi ethnic 1000 Genome reference panel 
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for comparison. Individuals were classified as AA or EA according to the 
reference panel population to which they more closely matched. SNP genotype 
imputation was performed separately in AAs and EAs using the March 2012 
1000 Genomes reference panel (1000 Genomes Project, 2012; 
http://www.1000genomes.org/) and IMPUTE2120 implemented on the Michigan 
imputation server (https://imputationserver.sph.umich.edu).	
Genetic Association Analysis 	 Association of opioid cessation with dosage of the minor allele of each 
SNP was evaluated using logistic regression models solved with generalized 
estimating equations (GEE) to correct for correlations among related individuals 
and included terms for age, sex and the first five PCs to correct for population 
sub-structure. Association testing was restricted to SNPs with an imputation 
score >0.8 and MAF >3%. Association tests were performed separately within 
each ethnic group and within each genotyping platform to account for batch 
effects. To prevent low frequency SNPs from inflating test statistics, a filter based 
on the effective number of minor alleles in cases (successful cessation) was 
used. SNPs with an effective number of minor alleles of fewer than 10 (Neff = 2 × 
N achieving successful cessation × imputation quality × MAF) were excluded. A cutoff of 10 
was chosen to control for type I error. For the CATS dataset, we obtained 
summary statistics of SNPs with MAF > 0.01 and imputation R2 > 0.3, logistic 
association was performed using PLINK v.1.9 121,122 adjusting for sex, age, and 
the first three PCs. We used a less stringent SNP inclusion criteria on CATS 
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dataset to maximize the variant overlap to our discovery dataset given CATS 
variants were genotyped on a different chip. Results were corrected for genomic 
inflation (λ) and combined across ethnic and batch groups via inverse variance 
weighted meta-analysis implemented in the program METAL123. The genome-
wide significance (GWS) threshold was set at p< 5.0×10-8. 
Power  	 Power for detecting significant association with opioid cessation in the 
study sample was evaluated, assuming α=5×10-8, power (1-β)=0.8 and an 
additive model, separately for AAs and EAs using a genetic power calculator124. 
These analyses indicated sufficient power to detect a variant with a MAF of 0.04 
and heterozygous genotype relative risks of 2.00 in AAs and 1.62 in EAs, or a 
variant with a MAF of 0.1 and heterozygous genotype relative risks of 1.70 in 
AAs and 1.40 EAs. 
Assessment of SNP Effects on Gene Expression 	 SNPs that surpassed a threshold of p<1×10-5 in the opioid cessation 
GWAS were assessed for their potential to affect gene expression using 
information in the Genotype Tissue Expression Portal (GTEx)125 (http://www. 
gtexportal.org) and Braineac (http://www.braineac.org/)126 databases. GTEx 
contains information that links SNP genotype to expression in multiple human 
tissues, whereas Braineac incorporates expression data for multiple brain 
regions derived from 130 individuals that were obtained from the UK Brain 
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Expression Consortium (UKBEC) and contains information of SNPs that can 
affect gene expression for multiple brain regions.  
Polygenic Risk Score (PRS) Analysis 
	 We generated PRS using the summary statistics for DSM-5 symptoms 
counts for opioid, cocaine and alcohol dependence among individuals who were 
exposed to the particular substance at least once from the combined Yale-Penn 
and CATS datasets. These PRS were regressed on opioid cessation status of 
Yale-Penn participants. Genome-wide association tests for these traits were 
performed using the same methods as described for the opioid cessation GWAS. 
Three significance thresholds (p<0.01, 0.001 and 0.0001) were used to identify 
the set of SNPs explaining the greatest proportion of the total trait variance within 
each ancestry group according to Nagelkerke’s R2 value using the PredictABEL 
R package127. For each threshold, correlated variants were removed by LD 
pruning (r2 >0.2) to avoid over-estimating the effect of variants in large genes. 
Weighted PRS were constructed using the allele dosage of the variants 
multiplied by their effect sizes. Opioid cessation of each ancestral group was 
then regressed on opioid, cocaine or alcohol use disorder severity PRS 
calculated in that ancestral group. Results were corrected for multiple testing 
using the Bonferroni method.  
	 Genetic overlap between opioid cessation and several OUD-related traits 
was also evaluated in the UKBB111. Relevant outcomes in the UKBB included 
“former drinker” or “ex-smoker” which reflects ability to cease use of other 
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substances, and “back pain for more than 3 months” which might indicate the use 
of illicit opioids for analgesic effect.  “Back pain for more than 3 months” was 
chosen instead of other pain-related traits because back pain is the most 
common form of pain and also a leading cause of disability128,129. We used 
PRSice130 to calculate PRS for these traits in order to estimate their genetic 
correlation with opioid cessation. These analyses were conducted for EAs only 
because the majority of participants in the UKBB are EAs. PRSice identifies the 
optimal p-value threshold that explains most of the trait variance for constructing 
PRS. PRSice models assume an additive effect for each SNP, and SNPs in high 
linkage disequilibrium (LD, r2>0.25) were removed using 200 bp sliding 
windows130. PRS were calculated by summing the product of the risk allele count 
reported in UKBB GWAS from opioid cessation samples multiplied by the effect 
reported in the UKBB GWAS. Results were corrected for multiple testing using 
the Bonferroni method.  
Pathway Analysis 	 Population-specific GWAS summary statistics were assessed for 
enrichment of functionally related genes using MAGENTA131.  MAGENTA 
combines individual variant association p-values into a gene score and computes 
a p value that is corrected for gene size, the number of variants, and LD. A 
nominal p-value is then calculated for each gene set, defined as the fraction of 
randomly sampled gene sets of identical size less than either the 95th or 75th 
percentile of gene score p values, after multiple testing correction. We used the 
 	
42 
75th percentile cutoff for significance since it demonstrates greater power for 
highly polygenic traits with weak effect associations131. 
 
RESULTS 	 In the Yale-Penn dataset, females had increased odds of cessation in AAs 
(OR=1.33, p=1.40×10-2) and EAs (OR=1.27, p=1.84×10-3). Age was associated 
with increased odds of longer cessation in AAs (OR=1.05 per year, P=8.34×10-
12) and EAs (OR=1.05 per year, p=2.00×10-20). In the CATS dataset, persons 
who ceased using opioids were 4.7 years older than those who did not 
(p=4.49×10-4). Although individuals with mild OUD were included, the mean 
number of OUD symptoms counts among participants in both datasets 
corresponds to a severe diagnosis.  
Genetic association findings for opioid cessation  	 There was no evidence of p-value inflation in either population group 
(Figure 2.2). Although no SNPs reached genome-wide significance (Figure 2.3), 
SNPs showed suggestive evidence of association (p<1×10-5) with opioid 
cessation were located in nine independent regions including three specific to 
EAs and six in the combined sample (Table 2.2). Several of these associations 
were supported by evidence with surrounding SNPs (Figure 2.4).  
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Figure 2.2. QQ plot of opioid cessation meta-analysis results.  
(A) AAs (Yale-Penn only), (B) EAs only (Yale-Penn +CATS), and (C) AAs and EAs 
combined. The genomic inflation factors for African Americans is 0.985, for European 
Americans is 0.981, and for combined is 0.991.  
	
(A) 
	 	
(B) 
	
(C) 
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Figure 2.3. Manhattan plot of opioid cessation meta-analysis results.  
(A) AAs (Yale-Penn only), (B) EAs only (Yale-Penn +CATS), and (C) AAs and 
EAs combined. Red line indicates genome-wide significant threshold (p = 5 × 10-
8), green line indicates sub genome-wide significant threshold (p = 1 × 10-6). 			(A)
		(B)	
	(C)	
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Table 2.2. Association findings for opioid cessation (p< 1× 10-5). 
  
 	
46 
  
 
	
Lo
ca
tio
n	
	
Ge
ne
	
Af
ri
ca
n	
Am
er
ic
an
s	(
AA
s)
	
Eu
ro
pe
an
	A
m
er
ic
an
s	(
EA
s)
	
AA
s+
EA
s	
O
R	
P	
D
ir
	
O
R	
P	
D
ir
	
O
R	
P	
7:5588
7138	
SEPT14
	
1.29	
1.06E-0
2	
+++	
1.50	
2.02E-0
5	
++-+	
1.39	
1.30E-0
6	
9:9783
693	
PTPRD
	
1.48	
4.33E-0
4	
++?	
1.25	
6.62E-0
4	
++++	
1.31	
2.24E-0
6	
2:7641
7353	
SUCLA
2P2	/	
AC073
091.2	
0.69	
2.20E-0
4	
---	
0.73	
4.11E-0
3	
----	
0.71	
3.09E-0
6	
12:197
67596	
AEBP2
	
1.36	
7.53E-0
3	
+++	
1.50	
1.41E-0
4	
+?++	
1.43	
3.37E-0
6	
8:2082
245	
MYOM
2	
0.93	
4.53E-0
1	
+--	
1.72	
4.11E-0
6	
++++	
1.22	
7.77E-0
2	
12:812
23948	
MIR61
7	
1.43	
5.37E-0
3	
++?	
1.48	
2.88E-0
4	
++++	
1.46	
5.84E-0
6	
20:100
86110	
SNAP2
5-AS1	
1.11	
5.48E-0
1	
+??	
1.44	
6.53E-0
6	
+-++	
1.24	
3.23E-0
3	
8:1218
47800	
RP11-7
13M15
.2	
/	RP11
-369K1
7.1	
1.27	
4.76E-0
2	
++-	
1.27	
7.45E-0
5	
++++	
1.27	
9.47E-0
6	
18:408
05792	
RIT2-S
YT4	
1.28	
3.03E-0
1	
+??	
1.74	
9.50E-0
6	
++++	
1.61	
3.22E-0
4	
 D
ir:
 e
ffe
ct
 d
ire
ct
io
n 
in
 th
e 
O
M
N
I, 
H
C
E 
an
d 
M
EG
A 
ar
ra
y 
sa
m
pl
es
 in
 Y
al
e-
Pe
nn
 d
at
as
et
 a
nd
 in
 th
e 
C
AT
S 
da
ta
se
t, 
re
sp
ec
tiv
el
y.
  
	
 	
47 
Figure.2.4. Locuszoom plot of association results.  
Linkage disequilibrium and recombination rate around the four biologically 
relevant loci (p <1×10-5) from meta-analysis of EA+AA datasets (panels A and B) 
or EA datasets only (panels C and D). The red line marks the genome-wide 
significant threshold. The LD estimate between top variants and its surrounding 
variants are indicated by color on the top left corner, where recombination rates 
were indicated by blue horizontal lines. The LD estimates in A and B are not 
present given the admixture population. Arrows on the horizontal blue lines show 
the direction of transcription, rectangles are exons.   	  
 	
48 
(A) 		
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Biological pathways and gene sets that influence opioid cessation 	 After multiple test correction, significantly enriched pathways were 
observed in EAs for vitamin D metabolism (padj= 3.79 ×10-2) containing nine 
genes while only three were expected (Table 2.3A) and fibroblast growth factor 
(FGF) signaling (padj= 2.39 ×10-2) containing 20 genes while only 10 were 
expected (Table 2.3B). No pathways were significantly enriched in AAs. 	  
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Table 2.3 Genes in significantly enriched pathways from MAGENTA in 
European Americans. 
 	 54 
(A)Vitamin D metabolism and pathway 
Gene Chr Start Pos. End Pos. Size (kb) 
Number 
of SNPs 
Number of 
independent 
SNPs 
Gene p-
value 
Top-ranked SNP 
ID Z-score p-value 
Odds 
Ratio 
COX15 10 101468504 101492423 24 197 5 1.14E-01 rs11190244 2.59 9.63E-03 0.85 
CYP2D6 22 42522500 42526883 4 217 8 2.18E-01 rs742086 2.33 1.98E-02 1.18 
CYP24A1 20 52769987 52790516 21 261 28 2.02E-01 rs1298513 2.88 3.92E-03 0.84 
CYP27B1 12 58156116 58160976 5 79 7 1.07E-01 rs182005106 2.37 1.79E-02 1.29 
POR 7 75544419 75616173 72 238 13 2.35E-02 rs11311523 3.16 1.56E-03 1.23 
RARA 17 38465422 38513895 48 15 11 1.30E-01 rs59214602 2.25 2.42E-02 1.20 
RARB 3 25469753 25639422 170 607 56 2.49E-01 rs17016192 2.87 3.77E-03 0.72 
RARG 12 53604352 53626036 22 65 11 1.23E-01 rs73309166 2.44 1.48E-02 1.36 		 	
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(B)   FGF signaling pathway.	
Gene Chr Start Pos. End Pos. Size (kb) 
Number 
of SNPs 
Number of 
independent 
SNPs 
Gene      
p-value 
Top-ranked SNP 
ID Z-score p-value Odds Ratio 
FGF2 4 123747862 123819390 72 255 15 1.05E-03 rs35287534 3.77 1.62E-04 0.76 
FGF3 11 69624735 69634192 9 203 33 1.15E-01 rs10908251 2.89 3.89E-03 0.78 
FGF4 11 69587796 69590171 2 249 36 1.66E-01 rs10908251 2.89 3.89E-03 0.78 
FGF5 4 81187741 81212171 24 279 21 1.72E-01 rs3796594 2.74 6.06E-03 0.74 
FGF6 12 4543307 4554780 11 177 19 1.37E-01 rs2244388 2.76 5.84E-03 0.83 
FGF7 15 49715374 49779523 64 361 10 1.74E-01 rs1583060 2.62 8.93E-03 1.34 
FGF12 3 191857181 192445388 588 887 71 1.76E-01 rs2221465 3.17 1.52E-03 1.24 
FGFR1 8 38268655 38326352 58 205 16 1.10E-01 rs10637920 2.67 7.03E-03 1.24 
FGFR3 4 1795038 1810599 16 103 7 6.72E-02 rs712983 2.65 8.13E-03 0.82 
FGFR2 10 123237843 123357972 120 366 42 5.64E-02 rs10886938 3.20 1.38E-03 0.79 
PPP2R1B 11 111597631 111637169 40 89 5 1.41E-01 rs61899413 2.27 2.34E-02 1.21 
PPP2R2C 4 6322304 6474326 152 416 56 2.30E-01 rs113823191 2.87 4.06E-03 0.72 
PPP2R5A 1 212458878 212535205 76 371 21 2.30E-01 rs11405845 2.57 1.02E-02 1.20 
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PPP2R5B 11 64692142 64701950 10 40 12 2.02E-01 rs56339918 2.24 2.55E-02 1.15 
PPP2R5D 6 42952329 42980080 28 257 7 4.83E-02 rs3805946 2.94 3.30E-03 1.19 
MAP3K6 1 27681669 27693337 12 79 10 8.97E-02 rs4246507 2.56 1.05E-02 1.19 
SPRY1 4 124317955 124324909 7 189 24 1.38E-02 rs300576 3.35 8.03E-04 1.37 
SPRY2 13 80910111 80915086 5 129 11 8.17E-02 rs9601380 2.68 7.29E-03 0.82 
MRPL38 17 73894723 73901181 6 199 11 1.18E-01 rs142057056 2.67 7.66E-03 1.50 
PEBP4 8 22570764 22785421 215 366 57 9.68E-02 rs200317753 3.05 2.27E-03 0.76 	
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Genetic correlation with other SUD traits  	 Table 2.4 shows that the PRS for severity of cocaine use disorder was a 
significant predictor of opioid cessation in AAs (p= 9.0×10-4), whereas the PRS 
for severity of alcohol use disorder was a significant predictor of opioid cessation 
in EAs (p =3.00×10-4). The PRS for severity of opioid use disorder was not 
associated with opioid cessation in either AAs or EAs. Among the traits 
considered in the UKBB dataset, the PRS for back pain persistent for more than 
3 months was significantly associated with cessation in EAs (p=1.25×10-7). 
Opioid cessation was also associated with PRSs for being a former drinker 
(p=6.24×10-4) and ex-smoker (p=4.44×10-3). However, the proportion of variance 
for opioid cessation explained by the trait PRS were small, ranging from R2= 
0.00747 for being an ex-smoker and R2= 0.0211 for having back pain for more 
than 3 months in EAs. 
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Table 2.4. Association and model fit between polygenic risk scores of traits 
related to opioid cessation in (A) African Americans and (B) European 
Americans.  
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 (A) 
 Trait  GWAS N  GWAS p 
threshold 
PRS Padj R2 
Yale-Penn 
dataset 
Alcohol 
severity 
score 
5,561 0.01 NS 4.50E-03 
Cocaine 
severity 
score 
4,015 0.001 9.00E-04 1.86E-02 
Opioid 
severity 
score 
2,275 0.01 NS 3.30E-03 
 
(B)  
 Trait  GWAS N  GWAS p 
threshold 
PRS Padj R2 
Yale-
Penn + 
CATS 
dataset 
Alcohol 
severity score 
7,655 0.01 3.00E-04 1.49E-02 
Cocaine 
severity score 
5,248 0.01 NS 4.50E-03 
Opioid 
severity score 
4,701 0.001 NS 6.00E-04 
UKBB 
dataset 
Ex-smoker 83,133 1 4.44E-03 7.47E-03 
Former 
drinker 
21,894 0.09185 6.24E-04 9.93E-03 
Back pain for 
>3 months 
84,489 
0.1822 1.25E-07 2.11E-02 
 
GWAS N: the sample size of the trait where the variants from the summary 
statistics were obtained.  
GWAS p threshold: the p value threshold for including a variant from the trait 
summary statistics for PRS construction.  
PRS Padj: the adjusted p-value for the trait PRS in a prediction model for opioid 
cessation. NS: not significant.  
R2 : the variance of opioid cessation explained by the trait PRS. 
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Discussion 	 To our knowledge, this is the first GWAS for opioid cessation. Although no 
genome-wide significant associations were identified in the EA group or in the 
combined sample of AAs and EAs, we obtained suggestive evidence for 
association of cessation from opioid use for at least one year among persons 
who were diagnosed with OUD with variants in several genes not previously 
linked to OUD. Pathway analysis that was seeded with summary GWAS 
information implicated two biological processes in successful opioid abstinence 
including vitamin D metabolism and FGF signaling. Analyses of PRSs computed 
for risk of other SUDs, ability to quit smoking or drinking, and persistent back 
pain suggest shared a genetic underpinning of these traits with opioid cessation.  	 Several of the top-ranked genes associated with opioid cessation have 
been implicated previously in substance use disorders or other psychiatric traits. 
Protein tyrosine phosphatase receptor type D (PTPRD) is abundantly expressed 
in CNS ventral midbrain neurons involved with reward, locomotor, and sleep 
processes in both mice and humans110,132, it is an important regulator of axon 
growth133. Myomesin 2 (MYOM2) encodes for a major protein in the muscular 
tissue, MYOM2 is nominally associated with nicotine and alcohol dependence in 
Australian and Dutch populations134. Synaptosomal-associated protein of 25kDa 
(SNAP-25) controls the release of neurotransmitters by modulating voltage-gated 
calcium channels135. Studies have linked SNAP-25 to response to antipsychotic 
treatment136, morphine-associated contextual memory retrieval137, and the risk of 
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ADHD138. The top variant rs592026 (Supplemental Figure 4D) in SNAP-25-AS1 
is located 113kb upstream of SNAP-25 and is also an eQTL for in SNAP-25 in 
thalamus (P = 1.8×10-4). 	 A role for vitamin D metabolism and FGF signaling pathways identified 
from biological pathway analyses that relied on evidence from GWAS in addiction 
relevant biology is supported by previous research. A neuroprotective effect of 
vitamin D against methamphetamine-induced dopamine depletion has been 
demonstrated.139 Vitamin D3 has been shown to reduce neuropathic pain by 
modulating opioid signaling in the rodent brain140. Low vitamin D level was 
observed in methadone maintenance patients141 and associated with a higher 
dose opioid for treatment of cancer patients.142 In addition, vitamin D inadequacy 
results in worse physical functioning and poorer health perception.143 One 
explanation for this observation is that individuals who cease opioid use might be 
more physically fit because of better vitamin D metabolism compared to 
persistent opioid users. Several other genes in the vitamin D metabolism 
pathway have been linked to opioids. CYP2D6 (P best_SNP = 0.02) is a member of 
the P450 family and encodes an enzyme that has many opioids substrates144. 
Polymorphisms in CYP2D6 can dramatically affect the metabolic capacity leading 
to under- or over-exposure to opioids145. CYP2D6 ultra-rapid metabolizers have a 
higher chance to experience adverse events with opioid prescriptions146. In the 
presence of opioids, RARA (P best_SNP = 0.02) forms a complex with RXRA, which 
activates mu-opioid receptor and modulates drug–seeking behaviors147. Some 
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mutations in the vitamin D receptor gene (VDR, Pgene = 0.04, P best_SNP = 0.001) 
have been associated with impulsivity in the context of alcohol dependence148. 	 The FGF pathway has been previously implicated in opioid metabolism. 
One study showed that FGF is involved in the development of analgesic 
tolerance to the opioid agonist morphine.149 In addition, the FGF receptor was 
identified as a converging site between mu-opioid receptor and growth factor 
signaling pathways150. One of the significantly enriched genes identified from this 
pathway, MAP3K6 (Pgene = 0.09, P best_SNP = 0.01), is differentially expressed in 
striatum and prefrontal cortex among chronic and acute morphine treated 
mice151. There are also links between vitamin D metabolism and FGF signaling. 
FGF23, a fibroblast growth factors that is highly expressed in bones, reduces 
levels of activated vitamin D152 and thus leads to reduced bone mineral density 
and a higher risk of fracture153. Interestingly, long term use of opioid analgesics 
has been associated with bone loss154. 	 PRS analysis revealed genetic overlap between opioid cessation and 
several other traits. Although the observed associations of opioid cessation with 
PRS for cocaine and alcohol symptom counts may be due to the ascertainment 
of our sample which is enriched for individuals dependent on cocaine and 
alcohol, shared genetic underpinnings between opioid cessation and risk of other 
SUDs is supported by studies in twins155 and unrelated individuals156. It is not 
surprising that chronic pain is genetically correlated with increased substance 
use among patients on methadone treatment 157. However, randomized clinical 
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trials suggest that patients with chronic pain do not receive a benefit from opioid 
treatment, but suffer from more opioid therapy adverse events128,158. The limited 
pain reducing property of opioids might explain the positive association between 
genetic predispositions to having chronic pain and opioid cessation. In addition, 
the Netrin-1 receptor gene DCC was found to be related to chronic opioid 
exposure and chronic back pain in both mice and human studies159,160.  	 Several limitations of our study should be noted. First, we used cross 
sectional data to study a phenotype that would require long-term follow up to 
more accurately define cessation. It is possible that some people who ceased 
opioids at the time of interview became users again. Second, we used a slightly 
different definition for cessation in the CATS dataset because these participants 
were recruited with multiple versions of the psychiatric interview instrument that 
resulted in a time frame of last opioid use that was less precise than that for 
subjects in the Yale-Penn dataset. This might limit the utility of CATS for 
replication. Third, several PRSs were constructed on phenotypes from Yale-Penn 
and CATS dataset, which has a decent amount of sample overlap to sample 
used for opioid cessation, this might affect the validity of the PRS results. Fourth, 
the opioid cessation GWAS sample had limited power for detecting robust 
association signals. For example, a sample of 300 additional cases would be 
needed to attain 80% of power for detecting genome wide significance with the 
top-ranked variant rs11767417 if the observed effect size is the true effect size. 
However, although only sub-genome wide significant associations were 
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identified, we observed supportive evidence for association of the top variants 
with adjacent SNPs (Supplemental Figure 4). Future studies with adequately 
powered samples should be conducted to validate some of our findings. Finally, 
although small, the proportion of variance for opioid cessation explained by the 
significant trait PRS is in the range of similar studies161. 
Conclusion 	 Although no genome-wide significant variants were found in this GWAS 
for opioid cessation, the top-ranked variants are located in genes previously 
linked to SUD traits that have important roles in neural growth and signal 
transduction in brain regions related to pain and reward systems. Pathways 
derived from genetic evidence suggest additional biological mechanisms that 
influence opioid cessation. 
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CHAPTER THREE: Identifying factors associated with opioid cessation in 
African Americans and European Americans using machine learning 
Abstract 
 
Background and Aims Opioid use disorder patients (OUD) who stop using 
opioids may or may not use pharmacological treatment. Racial disparities in OUD 
management exist, however, and there is limited research on factors that 
influence opioid cessation in different population groups.  
Methods: We employed multiple machine learning prediction algorithms 
(LASSO, random forest, deep neural network, and support vector machine) to 
assess factors associated with ceasing opioid use in a sample of 1,192 African 
Americans (AAs) and 2,557 European Americans (EAs) who met DSM-5 criteria 
for OUD. Values for nearly 4,000 variables reflecting demographics, alcohol and 
other drug use, general health, non-drug use behaviors, and diagnoses for other 
psychiatric disorders, were obtained for each participant from the SSADDA, a 
detailed semi-structured interview. 
Results: Support vector machine models performed marginally better on 
average than other machine learning methods with maximum prediction 
accuracies of 75.4% in AAs and 79.4% in EAs. Subsequent stepwise regression 
considered the 83 most highly ranked variables across all methods and models 
and identified less recent cocaine use (p<5×10-8), shorter duration of opioid use 
(p<5×10-6), and older age (p<5×10-9) as the strongest independent predictors of 
opioid cessation in both AAs and EAs. Attending self-help groups for OUD was 
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also an independent predictor (p<0.05) in both population groups, while less 
gambling severity (P =3.32×10-2) was specific to AAs and PTSD recovery (P 
=7.88×10-5), recent antisocial behaviors (P =2.69×10-3), and atheism (P 
=1.34×10-2) were specific to EAs. Factors related to drug use comprised about 
half of the significant independent predictors in both AAs and EAs, with other 
predictors related to non-drug use behaviors, psychiatric disorders, overall 
health, and demographics. 
Conclusions: These proof-of-concept findings provide avenues for hypothesis-
driven analysis, and will lead to further research on strategies to improve OUD 
management in EAs and AAs. 
 
Key words: opioid use disorder, opioid cessation, opioid abstinence, machine 
learning, AI, diagnostic questionnaire, feature selection, outcome prediction 
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Introduction 
 Use of illicit and misuse of prescription opioids is a significant global 
problem that affects the health and economic welfare of individuals, families, and 
society. The U.S. opioid overdose rate has quadrupled since 1991162. In 2017, 
more than 47,000 Americans died of an opioid overdose, and 36% of these 
deaths involved prescription opioids 100. A major goal in treating opioid use 
disorder (OUD) is abstinence, or complete cessation, of opioid use, other than 
the use of prescribed opioid replacement therapy. There is not a single, clinically 
accepted definition of cessation that specifies the length of abstinence required 
before an individual is no longer considered to have OUD 163,164. DSM-5 identifies 
sustained remission from OUD as a one-year period during which no criteria for 
the disorder (other than craving) are met 165.  
	 Population differences affect multiple aspects of the current epidemic. 
Although opioid use nationally is higher among European-Americans (EAs) than 
African-Americans (AAs), the opioid death rate has increased more sharply 
among AAs than EAs 166. AAs have less access to treatment for OUD 167, are 
less likely to obtain opioid prescriptions for pain management 168, and are 
incarcerated at a higher rate for illicit opioid use 169 than EAs. Previous research 
on OUD-related outcomes has been conducted primarily in combined ethnic 
groups or in EAs only 170, limiting the identification of key population differences 
in opioid use and treatment outcomes. 
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 Although moderately correlated with opioid cessation, factors contribute to 
opioid treatment completion such as age, employment status, and age at first 
drug use have been identified from a mixed ethnicity sample163. Other factors are 
likely to influence cessation, such as pain experiences, general health, and the 
use of antidepressants 171-173. Delineation of these factors could inform OUD 
treatment strategies that may differ across population groups; or could be useful 
for individuals with OUD who aim to reduce or stop their opioid use. However, 
studies thus far have tended to focus on a small number of clinically relevant 
factors such as the dosage, duration, and formulation of medication-assisted 
treatment of substance use disorders 174-176. Large epidemiological studies of 
OUD 177-179 comprised of thousands of potential predictors would allow a 
systemic, hypothesis-free query to identify factors predicting opioid cessation. 
 Statistical methods are generally limited in their ability to sort through large 
numbers of predictors180. Data mining using machine learning, which is 
particularly well suited for identifying predictive factors among thousands of 
variables 181,182, has successfully identified predictor variables for a diverse set of 
outcomes 183-187. Here, we applied multiple machine learning techniques to 
evaluate a large set of clinical, demographic, general health, and behavioral 
variables in a large, racially mixed cohort of individuals who were ascertained for 
genetic studies of substance use disorders, but not necessarily treated for OUD, 
to identify factors that influence opioid cessation (defined as self-reported last 
illicit opioid use and/or prescription opioids misuse > 1 year before the interview 
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date). Our study identified additional factors associated with cessation, including 
several that are population-specific. These findings support an individualized 
approach to improve the outcome of cessation attempts. 
Material and Methods 
Participants and Assessments  	 Participants for this study were selected from a cohort of 6,188 African 
Americans (AAs) and 6,835 European Americans (EAs) who were recruited for 
genetic studies of opioid, cocaine, or alcohol dependence between 2000 and 
2017 through advertisements and treatment clinics at Yale University School of 
Medicine, the University of Connecticut Health Center, the University of 
Pennsylvania, the Medical University of South Carolina, and McLean Hospital 
112,113. This cohort included affected sibling pairs and additional family members, 
as well as unrelated cases and controls. Probands with schizophrenia or bipolar 
affective disorder were excluded 112,113. Information about the use of various 
substances, demographics, general health, behavior, and other psychiatric 
illnesses was obtained by interview using the Semi-Structured Assessment for 
Drug Dependence and Alcoholism (SSADDA) 177,188. Substance use disorder 
(SUD) and psychiatric disorder diagnoses were established according to DSM-IV 
criteria. Institutional review boards from each recruitment site and Boston 
University approved this study, and written informed consent was obtained from 
all participants. 
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Opioid Cessation Definition 	 Participants who were eligible for this analysis met at least two DSM-5 
criteria for OUD, corresponding to a lifetime diagnosis of mild to severe OUD. 
Current opioid cessation was determined by the response to the question, “When 
was the last time you used an opioid drug (including illicit methadone).” This 
question was asked as part of a series of items asked about illicit or non-
prescribed use of opioids. Individuals who last used an opioid >1 year before the 
date of interview were considered to have achieved cessation and those whose 
last use of an opioid was <6 months before the interview date were classified as 
non-cessation. Persons who used opioids between 6 months and 1 year before 
the interview date were excluded from further analysis. Filtering steps yielding a 
sample of 1,192 AAs and 2,557 EAs for analysis is shown in Appendix-I. Figure 
S1.  
Phenotype Data Processing 	 Preprocessing of 3,956 SSADDA variables was performed prior to 
machine learning analyses. Variables with narrative or invariable responses, 
containing redundant information (e.g., specific date of different episodes, drug 
names), and with a response rate <90% were removed. Missing values for binary 
and categorical variables were recoded as indicator variables to accommodate 
missing responses. Missing values for continuous variables were imputed to the 
population group mean value. Missing values for ordinal variables related to 
recency of drug use were assigned the highest level indicating less recent use, 
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since the missing values tend to indicate “stopped using for a long time” 
according to other variables in the dataset. Z-score normalization (mean of 0 and 
variance of 1) was applied to continuous variables within each population to 
minimize scaling issues. The number of variables remaining after these steps 
was 3,315 in AAs and 3,738 in EAs. 
Machine Learning Analyses. 
	 AAs and EAs were analyzed separately based on population differences 
in the epidemiology of opioid use and OUD. Variables were grouped into three 
nested sets defining three analytical models to explore the prediction accuracy 
blind to the individual’s opioid or other drug use activities. This approach was 
adopted to enhance identification of non-drug use variables whose effects may 
be masked or confounded by variables related to drug use and are highly 
correlated with the cessation outcome. Model 1 contained all variables except 
those related to recency of opioid use that are strongly correlated with cessation 
(variable n=3,093 in AAs and n=3,503 in EAs). Model 2 further excluded all 
opioid-related variables (n=2,863 in AAs and n=3,252 in EAs). Model 3 further 
excluded all drug use variables, leaving only demographic, non-SUD diagnoses 
and behaviors, and other health-related variables (n=1,656 in AAs and n=1,907 
in EAs). Models were evaluated using four machine learning methods described 
in Supplemental Materials to identify variables predicting opioid cessation. We 
modeled different types of intra-variable relationships between predictors and the 
outcome using linear (LASSO) 189 and linear support vector machine with 
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recursive feature elimination (SVM) 190 and non-linear (random forest with 
recursive feature elimination (RF) 191 and deep neural network with feature 
selection (DNN) 192) techniques. These four methods were applied to capture 
predictive variables under different model assumptions and allow for different 
outcome-predictor relationships. Variables from each model that were associated 
with the highest accuracy reflected by either F1 score or area under the curve 
(AUC) and generated by each machine learning method were retained. The F1 
score is a harmonic measure of precision (true positive / [true positive + false 
negative]) and recall ( true positive / [true positive + true negative] ), defined by 
2*(precision * recall)/(precision + recall) at a given case/control split, and AUC is 
an overall evaluation of model performance that accounts for the true positive 
and false positive rates for all possible diagnostic splits 193,194. Both 
measurements were considered because of their popularity in clinical settings 195. 
The F1 score was used to assess accuracy due to limitations of the AUC, which 
includes bias when performed on imbalanced datasets as well as impractical and 
uninterpretable split points for evaluation 193,196. 
Statistical Methods for Testing the Association of Opioid Cessation with 
Phenotypic Variables  
	 To determine which variables selected by the machine learning methods 
independently predict cessation, we applied different cutoffs for the importance 
measurement of each machine learning method, namely the odds ratio (OR) for 
LASSO, coefficient197 denoted by weight for SVM, feature importance197 for RF, 
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and activation potential192 for DNN. For LASSO, we chose variables that yielded 
ORs >1.05 or <0.95. We applied the following criteria for selecting variables from 
SVM and RF analyses depending on the number of variables (n) selected for 
each model: (1) if n >200, the top 30% of variables measured by absolute weight 
in SVM or importance in RF were designated as high impact; (2) if 100 < n < 200, 
the top 50% were selected; and (3) if n<100, all variables were designated as 
high impact. For DNN, all selected variables were designated “high impact”. Joint 
association tests were performed using bi-directional stepwise logistic regression 
that included 83 “high-impact” variables that were culled from three models 
across four machine learning methods in the AA and EA datasets. Variables that 
yielded the highest Akaike information criterion (AIC) with p <0.05 from bi-
directional stepwise logistic regression were grouped into “drug related”, 
“behavioral”, “general health”, and “demographic” categories. 
Results 
	 Characteristics of the study samples are shown in Table 3.1. The sample 
included 1,069 unrelated AAs and 2,252 unrelated EAs, as well as 123 AAs and 
305 EAs participants who were members of families containing a pair of siblings 
both with either opioid or cocaine dependence. There is a higher proportion of 
females among individuals who ceased opioids in both AAs (OR=1.35, P=6.7 
×10-3) and EAs (OR=1.31, P=1.1 ×10-3) compared to those who did not cease. 
Furthermore, participants who ceased opioid use were older by an average of 3.2 
years in the AA group (P=1.0 ×10-10) and 6.1 years in the EA group (P=2.2 ×10-
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16) than those who did not cease. The mean number of lifetime DSM-5 OUD 
criteria met among those who ceased opioid use was not significantly different 
from those who did not cease.  
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Table 3.1. Participant characteristics. 
 
  Time since last use 
  < 6 month (not 
cease) 
>1 year 
(ceased) 
AAs 
(N=1192) 
Total N (% female) 701 (33.5%) 491 (40.5%) 
Age (Mean + SD) 42.6 + 8.5 45.6 + 8.3 
OUD Symptom Counts (Mean + SD) 7.8 + 2.4 7.6 + 2.5 
# of families (N in families) 35 (76) 23 (47) 
EAs 
(N=2557) 
Total N (% female) 1714 (34.4%) 843 (40.6%) 
Age (Mean + SD) 34.4 + 10 40.5 + 10.3 
OUD symptom Counts (Mean + SD) 8.8 + 1.9 8.4 + 2.3 
# of families (N in families) 114 (241) 31 (64) 
 
AAs: African Americans, EAs: European Americans, OUD: opioid use disorder. 
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Feature selection  
	 The F1 score was generally higher across models in both AAs and EAs 
using SVM than the other machine learning algorithms (Appendix-I. Figure S2), 
although the differences in F1 score across methods were generally small, 
especially for models 1 and 2. A detailed discussion of the performance of each 
method for the three models is provided in Appendix - I.  
	 Appendix-I. Figure S3 shows the overlap of high impact variables chosen 
by the four machine learning methods. LASSO “high impact” variables almost 
entirely overlap with those from the other methods, while DNN-selected variables 
overlap the least with other method-selected variables. The majority of variables 
selected by non-LASSO methods are unique to those methods, however, there 
was high overlap in “high impact” variables selected by SVM and RF. Age was 
among the five top-ranked variables consistently identified by each method for 
each model in both AAs and EAs (Appendix –I. Table S1).  
Factors Associated with Opioid Cessation  
	 Stepwise regression analysis that considered independent predictors 
among 83 “high impact” variables culled from all models and machine learning 
methods (Table 3.2) revealed that age was one of the most significant predictors 
of opioid cessation in both AAs (OR=2.44 per standard deviation (SD) increase in 
age P=1.41×10-12) and EAs (OR=2.00 per SD increase in age, P=5.74×10-9). 
Variables related to drug use comprised over 50% of the nominally significant 
predictors of opioid cessation in AAs (29 of 41) and EAs (27 of 50).  
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	 Drug related variables were among the most significant positive predictors 
of opioid cessation in AAs and EAs including recency of last cocaine injection 
(ORAAs=2.30 per level increase, PAAs = 9.11×10-6) or use (OREAs=1.91 per level 
increase, PEAs=3.30×10-15), while more years using heroin (ORAAs=0.55 per 
standard deviation (SD) increase, PAAs=5.78×10-6) or being older at first heavy 
opioid use (OREAs=0.56 per SD increase in age, PEAs=2.67×10-12) decreased the 
odds of the outcome. Other drug use variables predicted greater odds of 
cessation but were less significant, such as “More time since last had alcohol 
symptoms lasting >1 month” (ORAAs=1.45 per level increase, PAAs=2.84×10-3) 
(OREAs=1.34 per level increase, PEAs=4.13×10-5), “had 2 marijuana symptoms 
lasting >1 month” (ORAAs=2.13, PAAs=4.83×10-3) or “marijuana interfered with 
work or home activities” (OREA=1.67, PEA=1.61×10-3), “smoked less frequently 
after waking up” (ORAAs=1.75, PAAs=7.76×10-3) or the Fagerstrom Test for 
Nicotine Dependence (FTND) item “able to cut down smoking” (OREAs=1.28, 
PEAs=3.69×10-2). Having attended a self-help group for OUD (ORAAs=1.72, 
PAAs=1.41×10-2) or started attendance at an OUD self-help group sooner 
(OREAs=1.28 per level decrease, PEAs=2.4×10-3) also increased the odds of 
cessation. 
	 Several variables related to other mental health issues were also 
associated with opioid cessation. Self-harm (ORAAs=1.39, PAAs=1.96×10-2) or 
suicidal ideation (OREAs=1.2, PEAs=8.08×10-3) were associated with significantly 
higher odds of cessation. Prior history of a depressive episode lasting >1 week 
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(ORAAs=1.31, PAAs=1.66×10-2) or having drug-use associated depression 
(OREAs=1.64, PEAs=2.55×10-3) predicted higher odds of cessation. Pathological 
gambling severity (ORAAs=0.8, PAAs=3.32×10-2) and no anxiety for longer than six 
month (ORAAs=1.72, PAAs= 2.06×10-3) were significantly predictors of cessation in 
AAs. In EAs, recovering from an event causing PTSD assessed by the question 
“No fear in most disturbing/traumatizing event” (OREAs=1.93, PEAs=1.66×10-6), 
less recent antisocial behavior episodes (OREAs=1.35 per SD increase in time, 
PEAs=1.03×10-4), and unsafely raced cars (OREAs=1.78, PEAs=3.79×10-3) were 
associated with increased odds of cessation. 	 In AAs, female sex (ORAAs=1.91, PAAs=1.83×10-3) and fulltime employment 
(ORAAs=1.84, PAAs=1.82×10-2) were associated with a greater likelihood of opioid 
cessation, while having been raised primarily by a single parent (ORAAs=0.63, 
PAAs=1.3×10-2) was associated with not achieving cessation. Other significant 
predictors of opioid cessation in AAs included HIV positive status (ORAAs=2.47, 
PAAs=1.39×10-3), while in EAs, higher body mass index (OREAs=1.32 per SD 
change, PEAs=2.58×10-6), having asthma (OREAs=0.68, PEAs=1.22×10-2), higher 
household income (OREAs=1.15, PEAs=1.3×10-3), and being an atheist 
(OREAs=1.45, PEAs=1.34×10-2) were significant predictors.   
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Table 3.2. Stepwise regression results using all significant variables from 
all machine learning methods and models. 
(A) African Americans and (B) European Americans. 
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A) African Americans 
 Variable OR p-value 
Drug related Time since 1st opioid treatment* 1.56 1.90E-04 
 Older age at first opioid misuse$ 1.4 2.45E-02 
 Older age at first opioid symptoms$ 0.46 2.23E-05 
 Diarrhea after stopping opioid use 1.54 3.68E-02 
 Attended opioid self-help group 1.72 1.41E-02 
 Older age at first heavy use of opioids$ 0.73 2.70E-02 
 N years using heroin$ 0.55 5.78E-06 
 Depressed after reducing cocaine use 0.53 4.05E-03 
 Time since last injected cocaine* 2.30 9.11E-06 
 Time since last used cocaine* 1.82 9.19E-05 
 Time since last stayed high in cocaine* 1.41 2.93E-03 
 Used cocaine <11 times within year of interview 2.67 1.38E-03 
 Treated in outpatient program for cocaine use 1.88 4.06E-03 
 Time since of first cocaine craving* 0.71 1.59E-03 
 Never injected cocaine 2.53 1.75E-03 
 Often used marijuana more than intended to 0.40 5.67E-04 
 Mixed alcohol and drugs >3 times in 12 months 0.51 2.08E-03 
 Time since last had alcohol symptoms lasting >1 month* 1.45 2.84E-03 
 Drinking interfered with work/responsibility 0.60 2.71E-02 
 Time since last attended alcohol self-help group* 0.79 2.65E-02 
 Being alcohol dependent 1.73 2.56E-02 
 Smoked in dangerous situation >3 times  0.66 3.75E-02 
 Smoked less frequently after waking up 1.75 7.76E-03 
 Older age at first cigarette$ 1.31 6.24E-03 
 Gave up social activities because of smoking 1.82 1.73E-02 
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 Time since first had sedatives* 1.3 1.06E-02 
 Had 2 marijuana symptoms lasting a month 2.13 4.83E-03 
 Disclosed drug problems to professionals 1.53 2.00E-02 
 Number of years using sedatives$ 1.29 1.33E-02 
Behavioral Pathological gambling severity 0.80 3.32E-02 
 Time since last hurt oneself on purpose* 1.39 1.96E-02 
 Time since last had depression >1 week* 1.31 1.66E-02 
 Ever treated with medication or ECT for depression 1.75 4.33E-02 
 Heard delusional noises when awake 1.61 3.40E-02 
 No anxiety for >6 months 1.72 2.06E-02 
Other Health HIV positive 2.47 1.39E-03 
 Health has always been better than now 0.62 9.64E-03 
Demographic Female sex 1.91 1.83E-03 
 Raised primarily by single parent 0.63 1.30E-02 
 Current age 2.44 1.41E-12 
 Fulltime employment 1.84 1.82E-02 
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B) European Americans 
 
 Variable OR p-value 
Drug related More time since last cocaine use* 1.91 3.30E-15 
 Older age at first heavy opioid use$ 0.56 2.67E-12 
 Number of years using heroin$ 0.69 3.01E-07 
 More time since last cocaine injection* 1.85 2.38E-06 
 More time since last had alcohol symptoms that last >1 month* 1.34 4.13E-05 
 >20 outpatient visits for drug/psychiatric problems in the last year 1.76 9.56E-06 
 More time since opioid treatment initiation* 1.53 2.24E-06 
 Used cocaine >11 times in last year 0.47 1.09E-05 
 More time since first used opioid 1/week for >1 month* 1.41 1.10E-04 
 Have injected cocaine 2.01 1.66E-04 
 Older age at first heavy cocaine use$ 1.27 7.40E-04 
 Marijuana interfered with work/home 1.67 1.61E-03 
 More time since one started opioid self-help group* 1.28 2.40E-03 
 More time since last feel high on cocaine for >1 day* 1.33 1.15E-03 
 More time since last attended cocaine self-help group* 0.76 3.27E-04 
 Continued using stimulant for its psychological problems 0.54 2.27E-02 
 Heart slowed down when cutting down tobacco use 0.56 1.52E-02 
 Used tobacco but not addicted 0.60 3.72E-03 
 Disclosed problems with cocaine usage to professional 1.65 2.45E-03 
 Always able to cut down smoking 1.28 3.69E-02 
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Treated at outpatient drug program for 
cocaine 1.41 2.81E-02 
 Used opioid more than intended to 0.63 1.15E-02 
 Craved cocaine when cut down 1.42 1.05E-02 
 Maximum N drinks in 24 hours$ 1.15 1.61E-02 
 Ever smoked >1 pack of cigarette daily for  >1 month  1.16 2.16E-02 
 Stopped using stimulants for >3 month 1.99 2.38E-03 
  Drinking resulted in objections or problems with family and work 1.48 4.39E-03 
Behavioral Answered questions before they were completed as a child 0.73 2.24E-02 
 <3 ASP criteria in 12 month period 0.64 2.69E-03 
 Often failed to pay debts 0.68 2.17E-03 
 Suspended or expelled from school 0.67 2.16E-03 
 Number times in jail$ 0.85 1.05E-02 
 More time since last had suicide idea* 1.20 8.08E-03 
 Less recent since last had antisocial behaviors$ 1.35 1.03E-04 
 No fear of most disturbing/traumatizing event 1.93 1.66E-06 
 Avoided scenes that reminded of traumatic event 1.88 7.88E-05 
 Had OCD behaviors when depressed 0.49 3.23E-04 
 Feeling distracted 1.56 8.15E-04 
 Unsafely raced cars 0.56 3.79E-03 
 Found customers for prostitutes  0.68 4.04E-02 
  Depression always started with drug problems 1.64 2.55E-03 
 Had 8 depression symptoms 1.46 8.99E-03 
 More time since last had depression episode* 1.20 1.65E-02 
 Have outstanding emotional problem 1.63 5.55E-03 
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Other Health Have asthma 0.68 1.22E-02 
 Older age at heaviest weight$ 1.21 2.68E-02 
 Body mass index 1.32 3.59E-06 
Demographics Being an atheist 1.45 1.34E-02 
 Household income 1.15 1.30E-03 
 Current age 2.00 5.74E-09 
 
OR=odds ratio 
The values listed for each variable have been adjusted to take other variables 
into account.  
* Categorical variables. 1- “within the last two weeks”, 2- “two weeks to just under 
one month ago”, 3-“one month to just under six months ago”, 4-“six months to a 
year ago”, 5-“more than a year ago”. OR value indicates the impact of per level 
change.  
$ Continuous variables. OR value indicates the impact of per standard deviation 
change.  
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Discussion 
	 We employed both regression and non-regression-based machine 
learning approaches to evaluate the association of more than 3,000 variables 
related to SUDs and other psychiatric disorders, other health-related behaviors, 
and demographic variables with opioid cessation among EAs and AAs assessed 
in a cross-sectional study of opioid, cocaine, and/or alcohol dependence. We 
observed moderate-to-high predictive accuracy across all methods; SVM, on 
average, marginally outperformed the other methods. Although the specific set of 
predictive variables differed in EAs and AAs, a common profile emerged. People 
who ceased opioid use tended to be older, initiated drug use later in life, had 
used opioids for a shorter period, experienced fewer problems related to cocaine 
or alcohol use, were currently employed, and had recovered from other 
psychiatric disorders including depression and PTSD compared to those whose 
opioid use persisted. 
 Previous research using machine learning for addiction outcomes focused 
mainly on predictive accuracy, although a few studies attempted to identify and 
interpret specific variables that were associated with the outcomes 163,164,198,199. 
Acion et al. reported that ensemble super learning was superior to other machine 
learning methods, and used penalized regression, SVM, and neural networks for 
predicting SUD treatment success indicated by treatment discharge status in a 
Hispanic cohort 163. In that study, less than 10% of participants had problems 
with cocaine or illicit opioids and fewer than 30 potential predictors were 
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assessed. In contrast, we evaluated several thousand predictors, including 
detailed measures of drug-use activities and psychiatric disorders, and ranked 
the importance of the top-ranked variables with four distinct machine learning 
algorithms. Gowin et al. identified regional brain activity changes predicting 
relapse from imaging data on fewer than 70 methamphetamine-dependent 
patients without including any lifestyle factors 163. Che et al. applied deep 
learning to electronic health record data to identify people with short-term or long-
term opioid use or dependence 164. Similar to our study, they identified comorbid 
substance use and anxiety disorders as predictors 164. Several other studies 
used only regression-based methods to predict opioid and stimulant dependence 
200, cocaine dependence 201 and alcohol dependence 202, which might not capture 
other relationships among variables. Several of the non-regression-based 
methods we employed have also been applied in other studies, which focused 
mainly on MRI brain images as predictors of substance use disorder diagnoses 
184,185,187,198. 
  We identified several predictors of opioid cessation that were previously 
associated with OUD or OUD-related conditions including co-morbid drug use, 
antisocial behavior, suicidal thoughts, HIV infection, and asthma 203-208. Our 
finding that the majority of people who ceased opioids (60% in AAs and 66% in 
EAs) also ceased cocaine use is consistent with evidence of high rates of co-
occurring OUD and cocaine use disorder (CUD) 209,210. This finding also supports 
the use of treatment strategies that target both disorders 209,211 and suggests that 
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ceasing use of one substance might influence the ability to cease use of the 
other. Alternatively, ceasing both opioid and cocaine use may reflect self-
selection for inclusion in the genetic studies in which 43% of AA and 32% of EA 
participants included those ascertained for CUD. Our findings are also consistent 
with observations that a failure to address tobacco use lowers the efficacy of 
opioid cessation treatment 212 and that a behavioral intervention in patients with 
antisocial personality disorder reduces substance use 213. Unlike problems that 
are associated with other drug use, which predicts lower odds of opioid 
cessation, we found that cannabis use-related problems (e.g., two marijuana 
symptoms lasting a month, marijuana interfering with work) predicts higher odds 
of opioid cessation. This finding is puzzling and not immediately explainable. 
Previous findings of the co-occurrence of drug addiction, suicide attempts, 
depression, family conflicts, and PTSD, which may suggest bi-directional casual 
relationships 203-208, are consistent with our observation that better management 
of comorbid psychiatric problems (fewer recent suicide attempts and psychiatric 
symptoms) increases the likelihood of opioid cessation or vice versa.  
 We and Acion et al. identified age, employment status, and age at first 
drug use as factors for treatment success 163. The protective effect of older age 
may be due to ascertainment bias because persons who survived severe 
dependence are more likely to have stopped using opioids. Full-time employment 
likely reduces the time or urge for persons dependent on opioids to seek and use 
the drug. In addition, drug screening associated with some jobs may reduce the 
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likelihood of current opioid use 214. Quitting opioids also make it easier to 
find/maintain a job. The inverse correlation of age at first drug use and opioid 
cessation may reflect the increased difficulty of reversing the effect of long-term 
opioid exposure on the brain reward system 29 or increased severity associated 
with earlier onset.  
 Several significant predictors of opioid cessation related to non-substance-
related behavior were population specific. Although these findings may be due in 
part to differences between AAs and EAs in willingness to endorse these 
behaviors, previous studies showed that AAs were more likely than EAs to report 
prolonged gambling and problems associated with gambling 215,216. One 
explanation for our findings of significant associations of ceasing opioids with a 
self-reported HIV diagnosis in AAs is that OUD patients with severe or life-
threatening illnesses are more likely to seek or adhere to treatment 217, an idea 
supported by evidence that HIV-infected patients have better treatment outcomes 
for OUD 218-220. Alternatively, poorer general health may lead to reduced drug use 
221 (the so-called “sick quitter”). In contrast, antisocial behavior, recovery from 
PTSD, and being an atheist were predictive of opioid cessation in EAs only. Prior 
research may provide insight into these EA-specific patterns. One study reported 
antisocial behaviors in EA children were significantly associated with substance 
initiation while the association was less strong in AA children 222, although the 
impact on opioid use was not assessed. PTSD and being an atheist identified in 
EAs might be due to the racial difference in exposure to traumatic events and 
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belief diversities 223,224. For atheism, previous evidence about the effect of 
religion on SUDs is contradictory. One study showed that loss of religiosity 
between childhood and adulthood was associated with increased substance use 
while recent religiosity increased the odds of illicit drug use in the past year 225. 
Alternatively, we could have observed similar factors in AAs but the sample size 
in AAs might limit our ability in identifying such associations.  
 The current study has several strengths. First, because the input dataset 
contains thousands of variables related to drug use activities, psychiatric 
disorders, medical history, and demographics obtained from several thousand 
individuals meeting DSM-5 criteria for OUD, we were able to explore many 
factors in addition to those included in other studies. Second, both linear and 
non-linear machine learning methods were employed to model the true 
underlying relationship between the predictors and outcome, which increased the 
number of factors we identified. Third, we evaluated three models for each 
machine learning method in order to better understand the contribution of opioid 
and other drug use information. Fourth, we considered only independent 
predictors in the association analyses to prevent over-representation of 
correlated factors. Finally, although there is no published “gold standard” 
predictive model against which to compare our results, the 80% predictive 
accuracy we achieved is similar to that seen in other machine learning studies 
163,164,198,199. 
 Limitations of this work should be noted. First, given the cross-sectional 
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nature of our data and the over 90% relapse rate for OUD 226, many individuals 
classified as not using opioids may have subsequently relapsed to opioid use. 
However, it has been shown that prior abstinence is predictive of future 
abstinence, therefore people who ceased opioids are more likely to cease again 
even when relapse happened 227. Second, the machine learning analyses were 
based on samples that may have been underpowered to detect associations with 
some variables compared to other studies that included tens of thousands of 
individuals 228. Third, most persons in our cohort were evaluated prior to the 
current opioid epidemic and may not reflect recent secular trends in the 
prevalence and associated features of OUD. Fourth, associations of cessation 
with some variables and overall prediction accuracy may have been inflated 
because our analysis did not fully account for familial correlations. Fifth, in spite 
of the large number of variables that were included in the machine learning 
analyses, potentially important variables such as the reasons for first use and 
details of treatment and support programs were unavailable. However, we 
identified attending an opioid addiction self-help group as predictive of successful 
cessation, which is consistent with the reported benefit of self-help groups 229. 
Sixth, the rate of response to many interview questions was substantially higher 
in EAs, while the sample size was twice that of AAs, which could account for 
some of the observed racial differences in predictive models. Given these 
limitations, our findings require external validation in larger samples before they 
can be incorporated in prediction models for clinical purposes. Finally, while 
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some of the factors identified were plausible and consistent with prior studies, 
other factor such as atheism is not immediately interpretable, such as “Found 
customers for prostitutes”. Given that our research is atheoretical, results should 
be interpreted with caution and be validated before implemented in clinical 
practice. 
Conclusions  	 Using machine learning techniques with feature selection, we analyzed a 
large number of variables include demographic, behavioral, health and drug use 
activities and found variables in a wide range of domains that were associated 
with cessation. These included some that are consistent with prior literature, 
plausibly could be associated but have not been well studied, and do not have 
readily apparent explanations for their associations. Our findings suggest 
hypotheses for future studies and could inform how one might increase the 
likelihood of cessation with and without treatment. These results also support 
several widely known treatment strategies for OUD, such as treating psychiatric 
comorbidity, adding wraparound services like employment counseling, and 
simultaneously addressing polydrug use problems. Finally, in an era of 
increasing availability of digitized health-related records, our study provides a 
framework for disease outcome prediction using high dimensional phenotypic 
data purpose-collected via a research instrument. 
.
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CHAPTER FOUR: Cross-species Identification of Gene Networks and 
Enriched Pathways for Mouse Opioid Behaviors and Human Opioid 
Cessation 
Abstract 
 Mice and human share about 99% genetic gene homologs. The use of 
mice as a model organism permits a comprehensive approach with precise 
environmental controls for identifying the effects of genetic influence on addiction 
behaviors, including drug sensitivity and spontaneous withdrawal. While there is 
a growing literature on genetic factors underlying various addiction traits have 
been reported in mice, a limited number of studies have cross-referenced human 
findings in mice. This translational approach is especially relevant because it 
provides additional leverage to protect against the potential high false positive 
rate of human genome-wide association studies (GWAS) findings. Therefore in 
this study, we conducted weighted gene co-expression network analysis 
(WGCNA) on a reduced genetic complexity cross between mouse substrains that 
displaying differential opioid sensitivity and withdrawal behaviors owing to an 
underlying QTL on distal chromosome 1. We cross referenced trans-regulated 
gene homologs and pathways originating from this locus that were also 
correlated with mouse behavior and identified gene modules that could then be 
compared to opioid cessation associated genes from human GWAS. Among the 
top overlapping genes, two genes HNRNPU and GRB10 were identified to have 
translational addiction-relevance. Pathway analysis identified several enriched 
93 	
	
gene sets that were previously known to be regulated by opioids, as well as 
novel pathways that provide potential new mechanistic insights to the shared 
genetics between mice and human in response to chronic opioid use 
Introduction 
 The genetics of opioid addiction in human and animal models are heavily 
studied106,230-232. We identified variants that were associated with opioid 
cessation in people with opioid use disorder (OUD) through genome-wide 
association studies (GWAS). The genes of the top variants (Chapter Two) are 
highly expressed in brain and have relevance to addiction phenotypes and 
psychiatric traits. However, false positive genetic association results have always 
been a concern in GWAS interpretation233, which makes animal models attractive 
for exploring the extent of concordance between these two lines of evidence234. 
 Mouse models are an extremely useful tool for identifying the genetic 
factors contributing to addiction-relevant phenotypes235. The large overlap 
between mice and human gene homologs (99%)236 allows for cross-species 
translation to human73. Furthermore, the environmental and genetic factors 
influencing addiction behaviors in mice can be precisely altered and the tissue 
specific gene expression level in response to genetic and environmental 
alterations can be closely monitored with high-throughput sequencing 
techniques. These attractive features of mouse models overcome the ethical 
limitations in using human subjects and make it possible to study clinically 
relevant addiction traits in a refined manner. While many methods used 
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experimenter-induced abstinence and relapse237, measuring voluntary opioid 
cessation in mice remains to be challenging. Hyper-locomotion  induced by drug 
abuse is a heritable behavior that is linked to stimulation of the mesolimbic 
reward pathway92 and anxiety-like behavior is a hallmark of opioid withdrawal238. 
, Genetic analysis of these traits in mice might allow one to cross-reference and 
translate findings to human opioid cessation. 
 Weighted gene co-expression network analysis (WGCNA)239 evaluates 
the co-expression patterns of genes based on their connectivity using correlation 
methods. WGCNA permits integration of transcriptome data with both genetic 
and phenotypic data (e.g., behavior) to identify gene networks that are trait-
relevant and has been widely used in both human and mouse studies240,241. 
Tools that allow for cross-species comparisons are trending. GeneWeaver242 is a 
web based tool that integrates experimental results with published GWAS, 
quantitative trait locus, microarray, RNA-sequencing, and mutant phenotyping 
studies to identify gene-function associations across diverse experiments, 
species, conditions, behaviors or biological processes. GeneWeaver includes 
functions such as homology integration tool that allows translation across species 
and similarity measurement between gene sets for one to assess the degree of 
overlap. 
 The goal of the current study is to use WGCNA to refine the trans-
regulated gene list from mouse transcriptomic findings in response to opioid 
induced behaviors, so that more accurate results can be obtained when 
95 	
	
comparing with genes identified from human GWAS. A previous study of 
oxycodone (OXY) induced behavioral quantitative trait locus (QTL) mapping on 
F2 reduced complexity crosses derived from B6J and B6NJ F1 intercross 
identified distal chromosome (chr) 1 (163-190 Mb) as a solely responsible locus 
for opioid sensitivity and opioid withdrawal behaviors243. Previously, expression 
QTL analysis identified extensive trans-regulation of gene expression associated 
with genetic markers distinguishing C57BL/6 substrains243. A gene list with 3495 
genes was obtained by applying 0.5% FDR cutoff to control for false positive on 
trans-regulated genes244. We used this gene list in WGCNA to identify gene 
networks (modules) that were correlated with opioid addiction behaviors and 
conducted a cross species comparison with the gene list for human opioid 
cessation genes that top variants are in. Our findings provide a framework for 
cross-species reference between humans and mice in addiction genetics. 
Material and methods 
Mice 
 The founder mice C57BL/6J (B6J) and C57BL/NJ (B6NJ) mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME) at 7 weeks of age. 
B6J females were crossed to B6NJ males to generate B6J x B6NJ-F1 mice and 
then B6J x B6NJ F1 offspring were intercrossed to generate B6J x B6NJ F2 mice.  
Mice within the same cage receive the same treatment. F2 mice were selected 
based on genotypes at distal chr1 (from the SNP array; 163 Mb, 181 Mb) to 
backcross to B6J to generate mice that were either homozygous B6J (J/J) or 
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heterozygous (J/N) across distal chr1. Other variations on the genome were 
considered unlikely to affect the Mendelian trait of Day 2 OXY-induced locomotor 
activity, therefore we focused solely on recombination events at distal chr 1 (163-
190 Mb). 11 mice (4 females) with J/J genotype at chr 1 marker and 12 mice (3 
females) with J/N genotype at chr1 marker were tested.  
 
Previous Behavioral Testing, Tissue Collection, Transcriptome Analysis and 
trans-eQTL analysis  
  Appendix II is a detailed description of the methods. Behavioral studies 
including OXY conditioned place preference, OXY induced locomotor activity 
(measured in Day 2 and Day 4), and elevated plus maze were done by Lisa 
Goldberg243. The striatum were collected for mRNA sequencing 24 hours after 
elevated plus maze testing from 23 OXY-treated F2, who were either 
homozygous (J/J) or heterozygous (J/N) at the markers capturing a QTL on distal 
a chr 1 for OXY-induced locomotor activity (rs6341208-163.13 Mb, rs51237371-
181.32 Mb). Transcriptomic analyses were done by regressing VOOM245 
normalized gene expression levels to the chr1 marker, adjusting for sex. Trans-
eQTL analysis were done by regressing gene expression levels to 90 SNPs 
throughout the genome using a linear model with an additive model in R package 
Matrix eQTL246.  
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Weighted Gene Co-expression Network Analysis (WGCNA) 
 The differentially expressed genes from above were annotated by R 
BioMart247 package using musculus Ensembl database (www.ensembl.org). 
VOOM transformed read counts averaged over sample replicates on genes that 
were differentially expressed in response to chr 1 marker were used as the input 
for WGCNA239. Using WGCNA, we identified no sample outliers, where 
hierarchical clustering dendrogram was performed on the similarity measurement 
of normalized read count. Using 1-step network construction and module 
detection, correlated gene clusters were identified. In brief, Pearson correlation 
between genes were calculated to capture the linear-relationships between 
genes. A soft thresholding power of 10 was chosen based on the criterion of 
maximizing approximate scale-free topology (scale free topology model fit =0.9) 
and applied on the Pearson correlation matrix to get the “scale-free” adjacency 
matrix. The adjacency matrix was transformed to topological overlap measures 
(TOM) to account for neighborhood similarities. The co-expression modules were 
detected by hierarchical clustering from TOM, which yielded 14 gene clusters 
with between 61 and 1140 genes. Gene clusters (modules) were given different 
color names, with “grey” indicating genes that don’t belong to any specific 
modules. We further related behavioral traits and genotypes observed to these 
gene clusters (modules) for association, where the first principal component 
(module eigengene) of a given module was individually correlated to the traits 
mentioned above. Genes within modules identified with eigengene significance 
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(p<0.001) were retrieved and plotted against their significant level of a given trait 
defined by the absolute value of the correlation between gene and the trait. 
Module membership was defined as the correlation of the module eigengene and 
the gene expression profile.  
Gene Enrichment Analysis  
 Genes within modules whose eigengenes were significantly correlated 
(p<0.001) with a chr 1 marker were used and combined with human cessation 
GWAS top genes as input to Enrichr248, an online enrichment analysis tool with 
databases including Gene Ontology (GO) Biological Process, GO Cellular 
Component, GO Molecular Function, and KEGG. Enrichr uses Fisher’s exact test 
to calculate an enrichment score, the test for each pathway was computed by 
evaluating its observed rank and how much it deviates from expected rank using 
several random input gene lists. The final output includes p value from Fisher’s 
test and Z statistics from rank test as well as a combined score, which is 
calculated as log(p)*Z.   
 
Cross-species Reference Using GeneWeaver 
 To find the similarities between human GWAS genes to thousands of mice 
differentially expressed genes (DEGs), we used a less stringent cutoff (p<0.05, 
1765 genes) on human GWAS variant mapped genes whose p values were 
corrected by Li and Ji method249 for the effective number of independent SNP 
tests performed within each gene. Genes within trait-significant modules from 
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mice trans-eQTL genes were used as mouse input. Homologs between human 
and mouse gene lists mentioned above were identified with two types of 
comparisons – mouse significant module genes vs. human opioid cessation gene 
list stratified by modules as well as mouse all trans-eQTL gene lists vs. the 
human opioid cessation gene list - using “GeneSet Graph” tool from 
GeneWeaver (www.geneweaver.org)242 . “GeneSet Graph” allows one to 
visualize the intersections of genes from multiple datasets, where homologs of 
different forms of gene and species can be identified. The same two types of 
comparisons between two genes sets mentioned above were performed to find 
the similarity between two gene sets via “Jaccard similarity”250 tool from 
GeneWeaver, where the similarity coefficients were measured as the size of the 
intersection of two gene sets divided by the size of the union between two gene 
sets, its associated p values were returned as well.  
Results 
Chr1 marker and OXY-induced traits associated gene clusters 
 We identified 15 modules (co-expressed gene clusters) with the size 
ranging from 61 to 1140 genes among 3495 trans-regulated genes (Figure 4.1). 
Pink and purple module eigengenes were significantly correlated with chr1 
marker rs51237371 genotype (rpink=-0.87, Ppink = 5×10-8; rpurple=0.62, Ppink = 1×10-
3). Purple module eigengene was more significantly correlated with OXY-induced 
locomotor activities and spontaneous withdrawal behavior than pink module 
(rpink_d2_distance=0.51, Ppink d2_distance = 0.01; rpurple_d2_distance=-0.51, Ppurple d2_distance = 
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0.01; rpink_d4_distance=0.34, Ppink d4_distance = 0.1; rpurple_d4_distance=-0.55, Ppurple d4_distance 
= 6×10-3; rpink_prctopenarm=0.36, Ppink prctopenarm = 0.09; rpurple_prctopenarm=-0.42, Ppurple 
prctopenarm = 0.05).  Although the degree of the correlations were similar between 
pink and purple module eigengenes to genotype and behavioral traits, pink 
module eigengene was negatively correlated with chr 1 genotype and positively 
correlated with behavioral traits, while the opposite was true for purple. Sex was 
not correlated with any module.  
 Genes in both pink and purple modules showed significant correlation to 
behavioral traits (Figure 4.2). Genes in the pink module had stronger correlation 
to locomotor activity and OXY induced withdrawal (rpink_d2_distance=0.52, Ppink 
d2_distance = 4.9×10-9; rpurple_d2_distance= 0.35, Ppurple d2_distance = 2.4×10-3 ; rpink_ 
prctopenarm =0.35, Ppink prctopenarm = 1.7×10-4; rpurple_ prctopenarm = 0.41, Ppurple prctopenarm = 
3.2×10-4). In addition, genes in the pink module were significantly correlated with 
chr1 marker genotype, purple module genes were not correlated with chr 1 
marker genotype (rpink_chr1_marker =0.67, Ppink_chr1_marker = 8.9×10-16; rpurple_chr1_marker 
= 0.19, Ppurple_chr1_marker = 0.11).  
  
101 	
	
Figure 4.1 Module eigengene – opioid trait relationship among trans-
regulated genes in mice.  
Co-expressed gene clusters (modules) were shown with prefix “ME” and a name 
of a color. “sex” :sex of the mice, “rs51237371_1”: genotype of chr1 marker, 
which can be either J/J or J/N. “D2.Distance”: day 2 (first OXY exposure) 
locomotor activity between chr 1 marker J/J and J/N mice measured in meters.  
“D4.Distance”: day 4 (second OXY exposure) locomotor activity between chr 1 
marker J/J and J/N mice measured in meters. “prctopenarm”: percent of time 
spent in the open arm of elevated plus maze. For each cell, the level of 
correlation is shown followed by the p value in parentheses.   
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Figure 4.2 Scatter plots of gene significance against module membership 
of OXY-induced locomotor activity.  
The locomotor activity of the first OXY exposure (A), OXY-induced locomotor 
activity of the second OXY exposure (B), OXY-induced withdrawal (C),  and chr1 
marker genotype (D) using genes in pink and purple modules.  Gene significance 
is defined as the absolute value of the correlation between the gene and the trait. 
Module membership is defined as the correlation of the module eigengene and 
the gene expression profile. “rs51237371_1” indicates genotype of chr1 marker, 
which can be either J/J or J/N. “D2.Distance” indicates day 2 (first OXY 
exposure) locomotor activity between chr 1 marker J/J and J/N mice measured in 
meters.  “D4.Distance” indicates day 4 (second OXY exposure) locomotor activity 
between chr 1 marker J/J and J/N mice measured in meters. “prctopenarm” 
indicates percent of time mice stayed at the open arm of elevated plus maze. 
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Gene Set Enrichment of Chr1 Marker Associated Modules 
 One pathway was significantly enriched (Padj<0.05) using genes in the 
purple module whereas six pathways were significantly enriched using genes in 
the pink module (Table 4.1). No pathways with the same names overlapped with 
human enriched pathways. Combining human GWAS finding genes with purple 
or pink module for pathway enrichment tests did not result in any pathway that 
overlaps with the human findings.  
Genes that Overlap between Chr1 Marker Associated Modules in Mice and 
Human Opioid cessation 
 Among 1756 human genes and 73 genes within the purple module, 4 
genes DLST, MFN2, HNRNPU and EPDR1 overlapped.  Among 1756 human 
genes and 111 pink module genes, 5 genes TIAM1, ARHGAP12, SP4, RSF1 
and GRB10 overlapped. Among 1756 human genes and 3495 trans-regulated 
mouse genes, 232 genes overlapped. The overlap observed for each pair was 
small but significant (Ppink_module_to_human <0.002, Jaccard similarity (J) 
pink_module_to_human =0.003; Ppurple_module_to_human <0.002, J purple_module_to_human =0.0038; 
Pall_mice_trans_eqtl_to_human <0.002, J all_mice_trans_eqtl_to_human =0.0515).  
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Table 4.1 Enriched gene set using chr 1 marker associated modules in mice 
with and without genes from human opioid cessation.  
Purple, pink: module name. hubgene: the gene with the highest connectivity 
within a module. Representative genes: genes in the module that were also in 
the identified pathway. GWAS genes: 89 genes identified from human opioid 
cessation GWAS result adjusted for gene size and LD.  
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 N hubgene Enriched Pathways Padj representative genes 
purple 73 Fchsd2 
reduced number 
of immature B 
cells 
0.04 SPPL2A, ATP11C 
pink 111 Tspyl4 
Glycolysis and 
Gluconeogenesis
  
0.008 LDHA, GOT1, ENO1B, ALDOA 
   Mitotic G2-G2/M phases 0.036 
ACTR1A, HSP90AB1, FBXW11, 
PSME3, DYNLL1, BTRC 
   mTOR signaling pathway 0.003 
RRAGA, FBXW11, BNIP3, 
RAC1, EEF2 
   
Asparagine and 
aspartate 
biosynthesis 
0.004 GOT1, ASNS 
   ATP synthesis 0.004 ATP5B, ATP5A1 
   Distal sensory impairment 0.036 ABHD12, YARS, MFN2, GARS 
purple
+ 
GWA
S 
genes 
162  -   
pink+ 
GWA
S 
genes 
200  TRIB3 kinase 2.00E-05 
YARS, ARF1, TMED9, GOT1, 
ASNS, EEF2, LURAPIL, BSG, 
MICALL1, EIF4H, GARS, 
CHAC1, EIF3C, ALDOA, ATF4, 
C11ORF24 
   MAP3K7 kinase 7.00E-03 
NARS, APIS, MORF4L2, 
UBE2D3, SERBP1, GDI12, 
G3BP2, EIF4H, CDK1, HNRNPU, 
GARS, MZT1 
   CSNK2A kinase 7.00E-03 
YARS, NARS, ATP5B, CXADR, 
HSP90AB1, APIS, SERBP1, 
GDII, G3BP2, HNRNPU, CHD4, 
CDC25A 
   MAPK6 kinase 2.00E-02 
NARS, ATP5B, HSP90AB1, 
APIS, SERBP1, DNAJA2, GDI2, 
G3BP2, ASNS, GARS 
   MTOR 2.00E-02 
KMT2D, SERBP1, EIF4H, MFN2, 
HNRNPU, DLST, ADAR, CHD4, 
EEF2, CDC25A 
 
  
108 	
	
Discussion 
Overlapping Addiction Risk Genes in Humans and Mice 
 Among genes that overlap between Chr1 marker associated modules in 
mice and humans, two genes, HNRNPU and GRB10, have previously been 
associated with addiction-related behaviors. HNRNPU is heterogeneous nuclear 
ribonucleoprotein U, which encodes a protein that bind both RNA and DNA, and 
involved in the formation of ribonucleoprotein complexes. HNRNPU was 
identified as a gene with the most connectivity (hubgene) in mouse alcohol 
dependence-associated gene networks sampled from the nucleus accumbens251. 
HNRNPH, a protein in the subfamily of HNRNPU, is known to interact with an 
intronic SNP252,253, which leads to alternative splicing of the opioid receptor gene 
OPRM1 in humans254. Another protein in this subfamily, HNRNPH1, has also 
been studied for its influence on methamphetamine response in mice253,255. The 
second identified overlapping gene GRB10 encodes growth factor receptor 
bound protein 10. Mice lacking paternal GRB10 make fewer impulsive choices, 
such impulsive choices could contributes to pathological conditions such as 
gambling and drug addiction256. Variants in GRB10 were also identified for 
substance dependence in humans257. Other research on GRB10 were mainly 
about its potential tumor suppressing and cell renewal effects258-260. 
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Implication of Enriched Gene Set 
 No pathway terms overlapped between the mouse chr1 marker associated 
enriched gene sets and human opioid cessation GWAS enriched gene sets. 
However, pathways enriched in the human opioid cessation GWAS are known to 
interact with pathways identified from the mouse analyses. For example, the 
vitamin D metabolism pathway identified from the human opioid cessation GWAS 
has an effect in mTOR signaling261 identified in mice enriched gene set, although 
the representative genes of these pathways did not overlap. Vitamin D, a key 
player in vitamin D metabolism pathway, also inhibits B cell proliferation and 
blocks B cell differentiation and immunoglobulin section262, which might result in 
“a reduced number of immature B cells”. As “a reduced number of immature B 
cells” was identified as an enriched gene set from mice. Loss of B cells in both 
human and in animal models has been observed after chronic exposure to 
alcohol and opioids263,264. Glycolysis and Gluconeogenesis is a  enriched gene 
set from mice, and this gene set includes the process of cells converting glucose 
to lactate followed by the synthesis of ATP (glycolysis) and the process of 
glucose biosynthesis from non-carbohydrate precursors (gluconeogenesis)265. 
There is evidence of a link between chronic consumption of opioids and delayed 
insulin response to food ingestion, which leads to increased hepatic glucose 
production secondary to glycogenolysis266,267. Similarly, the FGF signaling 
pathway enriched in the human GWAS is also known to regulate energy 
metabolism268. However, whether the FGF signaling pathway and Glycolysis and 
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Gluconeogenesis pathway are functioning together in the presence of opioid 
remains to be studied.  
 
Limitations 
 Several limitations should be noted. First, the mouse model used for this 
analysis was not designed to study opioid cessation but rather to study OXY-
induced sensitivity and withdrawal. A study design using mice with chronic opioid 
exposure with and without long-term abstinence would better model the opioid 
exposure in human cessation. Second, although the environment factors can be 
precisely monitored and studied for addiction behaviors in mice, factors affecting 
opioid cessation that are unique to humans such as drug price and social-
economic factors could alter the outcome, and are challenging to model in mice. 
Opioid abstinence in mice would likely to be achieved by controlling the drug 
accessibility. In this study, using F2 reduced complexity crosses as a mouse 
model further decreased genetic complexity, which affects the number of genes 
identified for associations with addiction phenotypes thus limiting the degree of 
cross-species gene overlap. Fourth, only the striatum was analyzed in mice, 
other brain regions such as prefrontal cortex, which regulates brain reward, self-
control, and drug craving269, were not studied. Fifth, human brain transcriptome 
data was not available for this project. Having human striatal RNA-seq data from 
the same opioid cessation participants would give us a more direct comparison. 
Finally, the gene set enrichment software used in mice was different from the one 
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used in human, thus could lead to less comparable results. Due to the limited 
power, we didn’t find any enriched gene set using Enrichr in human and the 
enrichment software used in human from Chapter Two was using GWAS 
summary statistics as input, thus could not be applied directly to mice data. 
Conclusion 
 Using trans-regulated genes identified from F2 reduced complexity 
crosses that were previously shown to have different OXY-induced sensitivity 
and withdrawal behaviors caused by one or more polymorphisms in linkage 
disequilibrium with a chr 1 marker, we constructed a biological network based on 
the co-expressed gene modules in striatum.  We identified two gene modules 
that were associated with both the chr 1 marker genotype and behavioral traits. 
Cross-species gene homologs and pathways were identified between mouse 
OXY-related genes and human opioid cessation GWAS mapped genes.  Our 
findings suggest novel genes and potential pathway mechanisms that are shared 
between mice and human in response to chronic opioid use.		
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CHAPTER FIVE Discussion and Future Directions 
Summary 
 This dissertation investigated the genetic and non-genetic basis of opioid 
cessation defined by recency of last opioid use among people who meet at least 
mild lifetime OUD criteria. Additionally, we used a mouse model that displayed 
differential opioid withdrawal behaviors to find genetic overlap between mouse 
and human through gene co-expression network analysis and pathway analysis. 
 Research on opioid cessation is extremely sparse. This is likely due in part 
to high relapse rates and clinical ambiguity of cessation; therefore, the majority of 
studies have so far focused on treatment completion rates as the primary 
outcome174-176. However, this outcome has a selection bias whereby people who 
have received treatment are more likely to be included in the analysis. In 
contrast, using opioid cessation as the primary outcome allows inclusion of 
individuals regardless of their treatment status. These analyses, in theory, might 
have greater potential to detect factors related to opioid cessation that are 
independent from treatment status. 
 This thesis includes the first genetic study of opioid cessation (Chapter 
Two). Studies investigating the genetic basis of opioid use have typically focused 
on opioid dependence or OUD severity level39,40 rather than opioid cessation. We 
utilized all currently available genetic datasets (to the best of our knowledge) to 
study this phenotype. Although our sample size was much larger than most 
studies investigating outcomes related to opioid cessation, it is relatively small for 
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a GWAS, resulting in insufficient power to detect genome-wide significant 
associations. Nonetheless, the top signals identified can serve as a reference for 
similar research. 
 Our association study of non-genetic factors for opioid cessation (Chapter 
Three) is unique in two ways. First, compared with other studies, the number of 
variables derived from the structured psychiatric interview is multiple orders of 
magnitude greater than most other studies of this outcome. Second, we used 
both non-linear and linear machine learning models to identify many possible 
combinations of variables that are predictive of cessation. In addition, the 
analyses were performed using factors that were grouped in multiple ways to 
identify contributions of opioid-related, other drug-related, and non-drug variables 
that significantly and independently predict opioid cessation. Using this 
information, we identified factors related to treatment success or other drug use 
problems that have been previously reported by others, as well as novel factors 
some of which might not be immediately explainable. Our proof-of concept study 
provides a framework for identifying disease related factors in healthcare data 
and also generates hypotheses for future studies. 
 Finally, we used a mouse model that displays varied opioid response and 
opioid withdrawal behaviors to identify gene co-expression patterns related to 
opioid behaviors (Chapter Four). While opioid cessation is difficult to model in 
animals, opioid response and opioid withdrawal severity are traits likely to be 
associated with relevant cessation outcomes in humans. Using RNA-seq 
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profiling, we identified several pathways enriched with specific genes clusters, 
and while these pathways do not overlap completely with human findings from 
Chapter Two, these pathways have been shown to interact with each other with 
respect to opioids. Furthermore, our comparison of the top genes associated with 
opioid cessation in humans and opioid behaviors in mice revealed several gene 
homologs that are related to impulsivity in humans, a behavioral trait known to be 
strongly associated with addiction. 
Future Directions 
 The work presented in this thesis suggests several future directions for 
continued exploration of factors related to opioid cessation. First, an 
epidemiological study should recruit a larger number of individuals to study opioid 
cessation as a primary outcome. Analyses conducted in such a dataset would 
have higher statistical power than currently available datasets, and will also 
enable analyses for identifying robust associations with rare variants. In future 
genetic studies, it will be advantageous to collect both gene-expression and 
epigenetic data from the study sample in order to evaluate the casual relationship 
between genetics and the outcome of interest. Second, in large scale studies of 
drug addiction research, there should be a greater emphasis on collection of 
more in-depth information regarding drug related activity (e.g., treatment clinic 
attendance, treatment frequency, reason of first drug use) in order to increase 
precision and robustness of associations with genetic and non-genetic factors. 
Third, as computational models become more advanced, we should explore data 
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using more than one machine learning model on top of existing models, such as 
the hybrid methods (stack several machine learning models together). Fourth, 
increased focus of RNA-sequencing brain regions most relevant to addiction (e.g. 
nucleus accumbens) would allow development of tissue specific networks and 
creation of tissue-specific gene profiles for each withdrawal behavior. Finally, the 
framework employed in this thesis project for using both genetic and non-genetic 
data to identify disease relevant factors, as well as animal models to enhance 
human findings, could be applied to other diseases to provide genetic, molecular 
and behavioral insights for better disease management.		
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APPENDIX I 
Supplemental Methods for Chapter Three 
Least Absolute Shrinkage and Selection Operator (LASSO) 
 LASSO implemented in the R package ‘glmnet’270 was used for both 
feature selection and prediction. The shrinkage parameter lambda in the penalty 
term of LASSO regression was obtained using 10-fold cross validation on the 
training set 10 times. Separate accuracy criteria of either misclassification error 
or AUC were used to search for the lambda with the best model fit. The “1SE 
rule271” which aims to find the simplest model with comparable accuracy to the 
best model, was used to identify lambda whose cross validation error was one 
standard error unit from the lowest cross validation error on the training set. We 
identified the significant features by fitting lambdas on the training set. The test 
set accuracy was evaluated by using the class probability prediction of test set as 
an input to Scikit-learn197 (roc_auc_score and f1_score ) to obtain our final 
accuracy measures: F1 score and AUC.   
Support Vector Machine (SVM) with Recursive Feature Elimination 
 Linear SVM with recursive feature elimination was implemented using the 
Scikit-learn python package. A soft margin was included in the model to reduce 
overfitting. Briefly, we set the penalty parameter C by exhaustively searching the 
range of values between 2-20 and 28 that covers the recommended range 
proposed by Hsu et.al190 using 10-fold cross validation with balanced class 
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weights on the training set . We applied the parameter C chosen by either 
maximizing AUC or F1 score (whichever yielded the highest accuracy) in the 
training set for recursive feature selection. A feature’s importance, represented 
by its weight, was used as the input to the recursive feature elimination function, 
where 10-fold cross validation was used to find the combination of features that 
maximizes either AUC or F1 score (whichever yielded the highest accuracy). 
Selected features from each model were applied to the test set to obtain the 
overall test accuracy. Given that RFE only evaluates a limited number of feature 
importance criteria, only the linear kernel was used for its ability to yield a smaller 
feature importance space, such that the feature importance of each variable is 
explained by one value instead of a collection of similarity values in reference to 
other variables.  
Random Forest (RF) Recursive Feature Elimination 
 The RF recursive feature elimination approach was implemented using the 
Scikit-learn python package. We determined the ideal number of decision trees 
needed for the RF model by searching the recommended range of 27 to 211 
proposed by Oshiro et.al191 10-fold cross validation with balanced class weight 
on the training set. The decision trees that associated with the maximum AUC or 
maximum F1 score were individually chosen. A feature’s importance, 
represented by the Gini impurity272 measure proposed by Breiman273, was used 
to evaluate the importance of a variable by adding up the weighted impurity 
decreases for all nodes averaged over all decision trees. A feature’s importance 
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rank was used as the input for recursive feature elimination and 10-fold cross 
validation was used to find the combination of features that maximized either 
AUC or F1 score (whichever yielded the highest accuracy). Selected features 
from each model were included in the test set without any feature selection steps 
to obtain the test accuracy. 
Deep Neural Network (DNN)  
 The DNN approach was applied using Keras274 with a tensorflow 
framework. A 3-layer, fully connected feed forward DNN was constructed with 
two hidden layers using rectified linear units (Relu) as an activation function and 
a sigmoid function for the output layer. The training set that was used in the 
aforementioned methods was further split into a development set and validation 
set with 9:1 ratio with fixed case control ratios to minimize overfitting or 
inadequate training. The Adam optimization method was used to find efficiently 
the parameters associated with the ideal state of the DNN objective function. The 
Adam optimizer275 has been proven to be the start of art276-278 optimization 
method by incorporating the advantages of two most popular optimizations 
(RMSProp279 and AdaGrad280). We followed the suggested hyperparameter 
settings from the developer of the Adam optimizer275 and only tuned the learning 
rate. L2 normalization with various scales were performed on each layer to 
prevent overfitting. Cross validation of the development set and balanced 
accuracy were used to reduce bias for the hyperparameter search. Both 
weighted AUC and weighted F1 score on the validation set were used to 
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measure model performance.  
 Several methods have been proposed for feature selection using DNN, 
with the focus on reducing input dimensionality, such as sparse one-to-one, 
dropout feature ranking, and activation potential based192,281,282. We used the 
activation potential based method because of its proven performance in reducing 
the number of features, to obviate application of another filtering method coupled 
with DNN, and its simplicity and intuitiveness for selecting the number of 
important variables. Feature selection was performed according to the method 
proposed by Roy et.al192. Briefly, we computed the activation potential of each 
input feature connected to each of the hidden nodes in the first layer before 
applying Relu. Then, the average relative activation potential of each feature in 
each first hidden layer node was calculated by averaging the number of input 
features and training samples at each node. Relu activation was applied to the 
average relative activation potential to obtain the net positive contribution of each 
input feature. Input features were ranked and plotted against their net positive 
activation potential contribution. Important features were chosen based on their 
collective contribution of net positive activation potential. Because of bias 
associated with AUC in the presence of imbalanced dataset, the feature 
combination that associated with the highest F1 score in the validation set was 
used to obtain the accuracy on test set.  
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Performance of Machine Learning Algorithms  
 There was a consistent drop in accuracy from model 1 to model 3 across 
the four machine learning methods, although the difference between models 1 
and 2 is smaller than the difference between models 2 and 3 (Figure S2). The 
loss of accuracy across models was greater in AAs than in EAs.  The AUC 
generally demonstrated higher accuracy than the F1 score. Among the machine 
learning methods, SVM yielded the highest F1 score more frequently than the 
other methods across models in both AAs and EAs. Most notably, SVM had the 
best performance for model 2 in AAs and models 2 and 3 in EAs, although the 
differences in accuracy between SVM and the other models with high 
performance were small. The observation that SVM performed only marginally 
better than LASSO in both AAs and EAs was not surprising because SVM using 
a linear kernel and LASSO employ a linear model with regularization. Both SVM 
and LASSO selected uncorrelated features, however SVM also selected 
correlated features. Both RF and DNN showed some evidence for overfitting 
(result not shown), although the effect was relatively small that was reflected by 
an approximately 4% higher accuracy in the cross validation training set than the 
test set. The RF model may have been overfitted because the number of 
individual classifier decision trees was fixed. DNN generally requires a much 
larger sample size than the one available here, which might have limited its 
performance. 
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Appendix I Table S1. Five most significant variables ranked by feature 
importance for each machine learning method, stratified by model and 
population. 
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African Americans 
  Variable Rank p-value 
Model 1 LASSO Recency of last cocaine use 1 2.89E-07 
  Current age 2 5.39E-10 
  Recency of 1st opioid treatment 3 4.97E-06 
  Cocaine use severity 4 4.69E-03 
  N years using Heroin 5 2.80E-08 
 SVM Recency of last cocaine use 1 3.50E-08 
  Recency of last cocaine injection 2 1.38E-04 
  Current age 3 9.20E-07 
  N years using Heroin 4 7.68E-06 
  Recency of weekly cocaine use for 1 month 5 - 
 RF Recency of last cocaine use 1 4.38E-06 
  Recency of weekly cocaine use for 1 month 2 - 
  Used cocaine>11 last year 3 - 
  Didn’t use cocaine>11 last year 4 - 
  Recency of cocaine symptoms 5 - 
 DNN Recency of last cocaine use 1 1.04E-06 
  Recency of last cocaine injection 2 - 
  Recency of cocaine symptoms 3 1.11E-01 
  Current age 4 5.50E-08 
  Recency of weekly cocaine use for 1 month 5 - 
Model 2 LASSO Recency of last cocaine use 1 5.32E-15 
  Current age 2 3.96E-08 
  Cocaine use severity 3 1.24E-07 
  Recency of last tobacco use 4 1.62E-03 
  Recency first reported drug problems to professionals  5 9.65E-01 
 SVM Recency of last cocaine use 1 5.44E-07 
  Recency of weekly cocaine use for 1 month 2 - 
  Recency of cocaine symptoms 3 - 
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  Didn’t use cocaine>11 last year 4 2.61E-02 
  Used cocaine>11 last year 5 5.16E-02 
 RF Recency of last cocaine use 1 2.26E-06 
  Used cocaine>11 last year 2 - 
  Didn’t use cocaine>11 last year 3 4.38E-02 
  Recency of cocaine symptoms 4 - 
  Recency of weekly cocaine use for 1 month 5 - 
 DNN Age first used tobacco 1 9.42E-04 
  Had relationship for >1 year 2 6.54E-03 
  Longest time in days without using tobacco 3 - 
  Contacted relatives infrequently 4 - 
  Mixed drugs with alcohol >3 times 5 - 
Model 3 LASSO Current age 1 5.20E-11 
  HIV positive 2 8.55E-06 
  Blamed others for one's mistake 3 1.76E-03 
  Jobless for 6 month due to drugs/alcohol 4 2.93E-02 
  Currently unemployed 5 2.97E-04 
 SVM Current age 1 2.67E-09 
  N biological children  2 3.62E-02 
  Currently unemployed 3 3.94E-02 
  Age at maximum weight 4 - 
  N months employed last year 5 - 
 RF Current age 1 2.49E-09 
  Age at maximum weight 2 - 
  BMI 3 5.98E-06 
  N drug symptoms when having depression 4 1.13E-02 
  current weight 5 - 
 DNN N doctor visits for health problems 1 - 
  Current age 2 5.17E-11 
  Jobless for 6 month due to drugs/alcohol 3 1.49E-01 
  Treated for emotional, psychiatric or drug problems  4 3.51E-03 
  Visited treatment center once last year 5 1.25E-01 
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European Americans 
 
  Variable Rank p-value 
Model 1 LASSO Recency of last cocaine use 1 8.72E-19 
  Current age 2 9.96E-12 
  Recency started opioid treatment 3 9.31E-07 
  Recency of last cocaine injection 4 1.80E-04 
  Age last had antisocial behaviors 5 3.92E-06 
 SVM Recency of last cocaine use 1 1.01E-16 
  Recency of last cocaine injection 2 1.01E-06 
  Used cocaine>11 times in last year 3 3.10E-03 
  Age at maximum weight 4 5.46E-02 
  Current age 5 9.87E-03 
 RF Recency of last cocaine use 1 4.38E-06 
  Recency of cocaine symptoms 2 3.24E-03 
  Didn’t used cocaine>11 times in last year 3 2.79E-03 
  Recency of last cocaine injection 4 6.52E-03 
  Used cocaine>11 last year 5 - 
 DNN Recency of last cocaine use 1 4.79E-25 
  Recency first brought up opioid problems with professionals 2 - 
  Recency of last cocaine injection 3 1.07E-03 
  Age last smoked cigarettes 4 6.60E-21 
  No drunk driving arrests 5 - 
Model 2 LASSO Recency of last cocaine use 1 3.06E-18 
  Current age 2 1.27E-05 
  Recency of last cocaine injection 3 1.38E-08 
  Age last had antisocial behaviors 4 4.56E-06 
  Cocaine use severity 5 1.83E-07 
 SVM Recency of last cocaine use 1 3.14E-17 
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  Recency of last cocaine injection 2 1.74E-06 
  Didn’t use cocaine>11 last year 3 8.36E-05 
  Age at maximum weight 4 3.82E-02 
  Current age 5 1.64E-05 
 RF Recency of last cocaine use 1 3.13E-14 
  Recency of last cocaine injection 2 2.43E-06 
  Used cocaine>11 last year 3 - 
  Didn’t use cocaine>11 last year 4 8.16E-04 
  Recency of cocaine symptoms 5 - 
 DNN Recency of last cocaine use 1 1.42E-17 
  Didn’t hurt animal on purpose 2 - 
  Recency last stayed high from cocaine >1 day 3 2.83E-03 
  Recency had >2 cocaine symptoms 4 - 
  Recency had cocaine symptoms 5 - 
Model 3 LASSO Current age 1 2.36E-09 
  Current health has always been worse 2 7.62E-07 
  BMI 3 3.12E-13 
  Age last had antisocial behaviors 4 - 
  Depression started with drug problems 5 3.98E-03 
 SVM Current age 1 3.10E-08 
  Age at maximum weight 2 4.62E-03 
  Age last had antisocial behaviors 3 2.74E-07 
  BMI 4 5.89E-12 
  Current weight 5 - 
 RF Current age 1 5.10E-09 
  Age at maximum weight 2 2.36E-02 
  BMI 3 1.15E-04 
  Current weight 4 8.08E-02 
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  Max weight 5 4.51E-03 
 DNN Current age 1 2.13E-09 
  Bad mood after ECT or bright light therapy 2 - 
  Didn’t have OCD 3 - 
  No gambling withdrawal when cannot gamble 4 9.20E-02 
  Didn’t have sex with >10 people in a year 5 3.54 E-02 
 
“Rank”: relative importance of a variable measured by the specified method;  “-” : 
variable not selected by stepwise regression; LASSO: least absolute shrinkage and 
selection operator; SVM: support vector machine with recursive feature elimination; RF: 
random forest with recursive feature elimination; DNN: deep neural network with 
recursive feature elimination.  
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Appendix I Figure S1. Study subject derivation 
Derivation of African Americans (AAs) and European Americans (EAs) subjects 
in the Yale-Penn dataset who were ascertained from multiple substance use 
disorder studies and met criteria for cessation or non-cessation of opioid use. 
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Appendix I Figure S2. Predictive accuracy of four machine learning 
methods by model in African Americans (A) and European Americans (B). 
AUC and F1 scores derived from a common set of variables picked by the 
method (DNN, LASSO, RF, SVM) for each model. m1: model 1; m2: model 2; 
m3: model 3; DNN: deep neural network; LASSO: least absolute shrinkage and 
selection operator; RF: random forest; SVM: support vector machine; AUC: area 
under receiver operating curve; F1: F1 score.   
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B) 
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Appendix I Figure S3.  Number of overlapping “high impact” variables 
selected by each machine learning method based on the importance 
measurement in African Americans (A) and European Americans (B) for 
models (1), (2), and (3). 
Model 1 includes all variables except for those that are confounded with opioid 
cessation. Model 2 includes all variables in Model 1 except opioid-related 
variables. Model 3 includes all variables in Model 2 except drug related variables. 
The criteria used for ‘high impact’ variables of each machine learning method can 
be found from Materials and Methods section in the main text. Colors represent 
machine learning method: pink = LASSO, light yellow = SVM, light green =RF, 
light blue = DNN. 
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APPENDIX II 
Supplemental Methods for Chapter Four 
Behavioral Testing 
 The behavioral tests were done previously by Lisa Goldberg as 
described243, including OXY conditioned place preference in week 1 and 2, OXY 
induced locomotor activity in week 3, and elevated plus maze in week 4.  
 OXY conditioned place preference was done as described previously283 
using a 9-day protocol with 30-min test and training sessions. Initial side 
preference were assessed on Day 1 after animals received a saline injection and 
were allowed free access to both sides. On training days Day 2- Day 5, mice 
received either saline or OXY while being confined to the corresponding drug-
paired side. On Day 8, conditioned place preference to the drug-paired side was 
assessed, as on Day 1. For locomotor activity measurement, a 3-day protocol 
was used284-286. On Day 1 and 2, mice were injected with SAL, and on Day 3 
mice were injected with OXY, prior to immediate placement in the locomotor 
chamber. Activity was measured for 30-min post injection. Behavior in an 
elevated plus maze was assessed using a 5-day protocol. Mice received daily 
saline or OXY injections to induce dependence on Day 1- Day 4. On Day 5, 
emotional-affective component of spontaneous opioid withdrawal was measured 
in the elevated plus maze96. Percentage of time spent in the open arms [(open 
time)/(open time + closed time) *100)] was used as a primary metric: an increase 
in time spent in the open arms corresponds to opioid spontaneous withdrawal.  
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Tissue Collection  
 Striatal tissue was collected from 23 OXY-treated F2 for mRNA 
sequencing 24 hours after elevated plus maze testing. Mice were chosen if they 
were either homozygous (J/J) or heterozygous (J/N) at the markers capturing a 
QTL on distal chromosome 1 for OXY-induced locomotor activity (rs6341208-
163.13 Mb, rs51237371-181.32 Mb), which resulted in a sample size of 11-12 
per genotype (3-4 females, 7-9 males per genotype). Brain tissue harvest, total 
RNA extraction and library preparations were done as previously described286 by 
Lisa Goldberg. As a result, the 23 samples were run on 5 lanes (technical 
replicates) in parallel on an Illumina flow cell by Illumina HiSeq 4000 machine, an 
average of 69.4 million reads per sample was obtained. FASTQ files were quality 
checked via FASTQC, with Phred quality scores > 30 (i.e. less than 0.1% 
sequencing error). 
 
Transcriptome Analysis  
 Using Rsubread287, FASTQ files were used to align reads to the reference 
genome (mm10; UCSC Genome Browser) and read counts per gene were 
quantified. Genes with minimum of one read across all quadruplicates as well as 
a minimum of one count per million in at least 25% of the count files were 
included. The read counts of each gene were normalized by VOOM 
transformation245 using R package limma245. For each sample, we regressed the 
gene expression level to the Genotype (across the Chr 1 QTL interval), adjusting 
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for sex; sample replicate was treated as a random effects measure to estimate 
within-sample correlation. 
  
Trans-eQTL Analysis 
 Differential gene expression in response to trans-located markers were 
done as previously described243. FASTQ files from each sample were summed 
across technical replicates and aligned to reference genome (mm10; UCSC 
Genome Browser) using Rsubread288. Genes with at least one fragment per 
kilobase of transcript per million mapped reads across all samples were used for 
the analysis. Expression levels of 12739 genes were regressed to 90 SNPs using 
a linear model with an additive model in R package Matrix eQTL246. Trans-eQTL 
was defined as any SNP in the panel that regulated genes on a different 
chromosome through expression. Genes possessing significant trans-eQTL were 
defined by a FDR cut off of 0.5%, which yielded 3495 genes. 
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